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Abstract: Background & Aims: Changes to the microenvironment of pancreatic ductal
adenocarcinomas (PDACs) have been associated with poor outcomes of patients. We
studied the associations between composition of the pancreatic stroma (fibrogenic,
inert, dormant, or fibrolytic stroma) and infiltration by inflammatory cells and times of
progression-free survival (PFS) of patients with PDACs after resection.
Methods: We obtained 1824 tissue microarray specimens from 385 patients included in
the European Study Group for Pancreatic Cancer trial 1 and 3 and performed
immunohistochemistry to detect alpha smooth muscle actin, type 1 collagen, CD3,
CD4, CD8, CD68, CD206, and neutrophils. Tumors that expressed high and low levels
of these markers were compared with patient outcomes using Kaplan-Meier curves
and multivariable recursive partitioning for discrete-time survival tree analysis.
Prognostic index was delineated by a multivariable Cox-proportional-hazards-model of
immune cell and stromal markers and PFS.
Findings were validated using 279 tissue microarray specimens from 93 patients in a
separate cohort.
Results: Levels of CD3, CD4, CD8, CD68, and CD206 were independently associated
with tumor recurrence. Recursive partitioning for discrete-time survival tree analysis
identified a high level of CD3 as the strongest independent predictor for longer PFS.
Tumors with levels of CD3 and high levels of CD206 associated with a median PFS
time of 16.6 months and a median prognostic index of –0.32 (95% CI, –0.35 to –0.31),
whereas tumors with low level of CD3 cell and low level of CD8 and high level of CD68
associated with a median PFS time of 7.9 month and a prognostic index of 0.32 (95%
CI, 0.050–0.32)—we called these patterns histologic signatures.
Stroma composition, when unassociated with inflammatory cell markers, did not
associate significantly with PFS. In the validation cohort, the histologic signature
resulted in an error matrix accuracy of predicted response of 0.75 (95% CI, 0.64–0.83;
accuracy P<.001).
Conclusions: In an analysis of PDAC tissue microarray specimens, we identified and
validated a histologic signature, based on leukocyte and stromal factors, that
associates with PFS times of patients with resected PDACs. Immune cells might affect
the composition of the pancreatic stroma to affect progression of PDAC. These findings
provide new insights into the immune response to PDAC.
Key words: ESPAC, pancreatic cancer, histologic analysis, prognostic factor
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To  
 
Prof. Dr. Richard Peek, 
Editor-in-Chief 
 
Prof. Dr. Ashok K Saluja 
Section Editor Pancreas 
Gastroenterology 
Ihr Zeichen: 
 
Unser Zeichen: 
Prof. Mayerle/bs 
 München, den 19.07.2018 
Submission of revision to Gastroenterology: Immune Cell and Stromal Signature 
Associated with Progression-free Survival of Patients with Resected Pancreatic 
Ductal Adenocarcinoma by Mahajan and co-workers. 
 
Dear Professor Saluja, dear Ashok 
Dear Professor Peek, 
Thank you for allowing us to submit a revision of our recent manuscript on a “ Immune Cell 
and Stromal Signature Associated with Progression-free Survival of Patients with Resected 
Pancreatic Ductal Adenocarcinoma”. We have now conducted a number of experiments to 
address your and the reviewers concerns and are able to show that in an independent 
validation cohort regardless of the staining technology applied the signature derived from the 
ESPAC-TPlus cohort is reliable and robust. We are excited about our findings and hope that 
you will be equally excited. Below you can find our point to point response. We hope that the 
revised version of our manuscript will now be acceptable for publication in Gastroenterology.  
Best, 
Julia and Markus 
 
Cover Letter
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Dear Professor Saluja, dear Ashok 
Dear Professor Peek, 
Thank you for allowing us to submit a revision of our recent manuscript on a “Prognostic 
histological signature based on interaction of immune cell infiltration with stromal composition for 
resected pancreatic ductal adenocarcinoma. We have now conducted a number of experiments 
to address your and the reviewers concerns and are able to show that in an independent 
validation cohort regardless of the staining technology applied the signature derived from the 
ESPAC-TPlus cohort is reliable and robust. We are excited about our findings and hope that you 
will be equally excited. Below you can find our point to point response. We hope that the revised 
version of our manuscript will now be acceptable for publication in Gastroenterology. 
Best, 
Julia and Markus 
Response to comments from the editor: 
Your manuscript was reviewed by two experts in the field and the Board of Editors. While all of 
us think that your study will make an important contribution, some additional data will strengthen 
your study.  
We are particularly interested in data validating your low vs high assignment on IHC by 
comparing it with traditional FACS analysis of a few of the immunological subsets.  
We would like to thank the editor for raising this question. To compare the results obtained by 
immunohistochemistry of TMA to traditional FACS analysis, we isolated intratumoral cells (ITCs) 
from 10 resected PDAC samples (provided by the Biobank of the Department of General, 
Visceral and Transplantation Surgery, Ludwig-Maximilians University (LMU), Munich, Germany 
under the administration of the Human Tissue and Cell Research (HTCR) Foundation, ethical 
approval number 025-12). To extend the analysis and compare all possible modalities to FACS 
analysis and classical immunohistochemistry, we used a three-tier comparison. This includes 
comparison of FACS immune markers with classical immunohistochemistry of tissue-blocks 
(TMA), immunocytochemistry on cytoblocks prepared from isolated intratumoral cells (ITCs) and 
immunocytochemistry on cytospins prepared from ITCs. We stained each of these samples for 
CD3, CD4, CD8, CD68 and CD206 expression. We quantified the staining for comparison with 
FACS data as percentage of positive cells as well as the number of cells per mm2 as described 
in the materials and methods section. We stratified the immunohistochemistry results into a low 
and high expression cohort using cut-offs reported in suppl table S1. As internal control we 
used FACS analysis of peripheral blood derived monocytes (PBMCs).  
We performed multiple correlation analyses and incorporated the correlation matrix of different 
immunostainings as scatter plots for distribution stratified for low and high expression as shown 
in suppl fig.S4. 
We observed a strong correlation between immunohistochemistry on tissue-blocks when 
compared with traditional FACS (solid black square in correlogram in suppl fig.S4). 
Point by Point Response
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Furthermore, we found a strong correlation between the percentage of CD3 cells in tissue-blocks 
and the percentage of CD45+CD3+ cells (R=0.64, p=0.04). We found a similarly robust 
correlation for CD8 (R=0.72, P=0.01), CD68 (R=0.73, P=0.01) and CD206 (R=0.87, P=0.001) 
when compared with immunohistochemistry on tissue-blocks and traditional FACS analysis. 
Overall, we found a highly significant strength of agreement between immunohistochemistry 
staining of immune markers in tissue blocks and FACS analysis of ITCs. 
To note, we did not find any correlation between immunohistochemistry on tissue-blocks and 
traditional FACS analysis performed on PBMCs (dotted black square in correlogram in suppl 
fig.S4 suggesting that the local tumor immune response is not reflected systemically on the level 
of surface markers on immune cells. 
We have included these analyses in the materials and methods section of  the main manuscript 
on page number 8 and a figure as suppl fig.S4. 
Also, data from multiplex immunoassays, given that these are now validated and provide the 
opportunity for quantification and permit co-localization of markers (e.g. Lisa Coussens Cell April 
2017), will be very helpful and reinforce your conclusions.  
We thank the editor for his suggestion. To confirm our finding by multiplex immunostaining and 
hereby study tumor heterogeneity, we introduced an independent validation cohort consisting of 
93 patients (CONSORT diagram in suppl fig.S9). We performed serial immunostainings of CD3, 
CD4, CD8, CD68, CD206, MPO, α-SMA and collagen, followed by multiplex immunostaining 
analysis. The flow of multiplexing analysis and quantification is shown in suppl fig.S11.  
Representative multiplex immunostainings of a PDAC TMA and a tonsil (control) are shown in 
suppl fig.S10A. We performed image cytometric analysis from multiplex immunostainings. On 
comparison of the number of CD3+ cells/mm2 on immunohistochemistry with the percentages of 
CD45+CD3+ cells by image cytometry, we found a positive correlation with R=0.79, P<0.001 
(suppl fig.S10B). Subsequently, we found a positive correlation between the number of CD4+ 
cells/mm2 and the percentage of CD45+CD3+CD4+ cells (R=0.73, P<0.001). We observed similar 
positive correlations for CD8 (R=0.31, P=0.02), CD68 (R=0.40, P<0.001), CD206 (R=0.80, 
P<0.001) and MPO (R=0.24, p=0.02). We also compared percentages of α-SMA+ cells with α-
SMA H-score and found a positive correlation (R=0.59, P<0.001, suppl fig.S10B).  
After establishing the correlation between single staining with multiplex immunostaining in our 
independent validation cohort, we aimed to validate the prognostic signature delineated from the 
identification study performed on the ESPAC-Tplus samples. We performed survival analyses 
for high and low expression of CD3, CD4, CD8, CD68, CD206, MPO and stromal composition 
and observed a similar prognostic association with PFS, as in the ESPAC cohort (suppl 
fig.S10C). Results from the validation cohort confirmed our finding that an absence of infiltrating 
T-lymphocytes is associated with decreased PFS. However, contrary to the ESPAC cohort, we 
did not find a significant association between high and low CD68 counts and PFS in the 
validation cohort.  
We validated the prognostic histological signature from the identification cohort using the 
validation cohort (see consort diagram suppl fig.S9, n=93). To achieve this, we predicted the 
response of the prognostic histological signature derived from the ESPAC cohort. The readout of 
predicted response was terminal nodal localization (categorization into prognostic subgroup by 
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IHC signature) and predicted median progression free survival of subjects of the validation 
cohort with respect to prognostic signature subgroup. We plotted an alluvial plot depicting 
prediction accuracy of the response (predicted median progression free survival time per 
subgroup) in comparison to actual response (actual median progression free survival time per 
subgroup) (see fig.3D, we revised figure 3 and now panel D shows the alluvial plot). Left side of 
the alluvial plot depicts predicted response per subgroup and the right panel depicts actual 
response per subgroup. The blue bar connecting left to the right graph represents perfect match 
while the red ribbon shows a mismatch in the response. The thickness of the bar or ribbon is 
representative of the number of subjects. Our prediction analysis revealed Cohen’s Kappa as 
0.69 with a Harrell’s C-index of 0.60. Cohen’s kappa is a measure of concordance and values in 
the range of 0.64-0.80 depict good concordance. The C-index is a measure of quality fit for 
binary outcomes in a logistic regression model and indicates the probability of a randomly 
selected patient experiencing an event burdened with  a higher risk score than a patient who had 
not experienced the event. A value of greater than 0.5 represents good predictability of the 
model. 
We substantiated our conclusion, by plotting Kaplan-Meier curves of predicted responses and 
actual responses (suppl fig.S10D). We observed an accuracy of prediction in the validation 
cohort using the prognostic signature with 0.75 (95%CI: 0.64-0.83, accuracy P<0.001). We 
found a positive correlation between predicted response and actual response R=0.62 and 
P<0.001. From our data we draw the conclusion that our prognostic model has good 
reproducibility and robustness. 
We have included these data in the main manuscript on page number 16 and as figure in panel 
D of figure 3 and suppl fig.S10. 
Furthermore, after validation of the prognostic signature using conventional morphometric 
analysis we tested whether the prognostic signature is still robust if we employ cytometry of the 
multiplex immunostaining. In cytometry results are expressed as percentage of positive cells as 
in conventional FACS analysis and thus cut-offs for dichotomization cannot directly be translated 
from one quantification method (Multiplex immunostaining on a single TMA but analysis of each 
staining cycle as individual staining versus merging all the stainings of a TMA in one image and 
analyzing it by image cytometry) to the other. We dichotomized CD45+CD3+cells, 
CD45+CD3+CD4+ cells, CD45+CD3+CD8+ cells, CD45+CD68+ cells, CD45+CD206+ cells and 
CD45+MPO+ cells into high and low percentages using the cut-off described below (table R1).  
Table R1: Cut-off for low/high expression determined by cut-off finder for the immune 
markers identified by image cytometric analysis 
Sr. No Marker Low expression High expression 
1 CD45+ cells$ ≤ 45.28 > 45.28 
2 CD45+CD3+ cells$ ≤ 5.23 > 5.23 
3 CD45+CD3+CD4+ cells$ ≤ 37.13 > 37.13 
4 CD45+CD3+CD8+ cells$ ≤ 6.47 > 6.47 
5 CD45+CD68 + cells$ ≤ 16.88 > 16.88 
6 CD45+CD206+ cells$ ≤ 38.62 > 38.62 
7 CD45+MPO+ cells$ ≤ 11.29 > 11.29 
8 ASMA+ cells$ ≤ 47.64 > 47.64 
$ Percentage of positive cells analyzed by Image cytometric analysis. 
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Predicting the response and nodal localisation/patients’ subgroup, using above immune markers 
derived from the image cytometric analysis, we observed a strong concordance between 
predicted response and actual response (Alluvial plot, fig. R1). We determined Cohen’s Kappa 
with 0.67 with a Harrell’s C-index of 0.56 confirming the robustness of the prognostic histological 
signature even using a different way of image processing and analysis. 
 
Figure R1: Multiplex immunostaining followed by image cytometric analysis in validation cohort. 
Alluvial plot depicting prediction accuracy of response (predicted m(pfst) per node) in comparison with 
actual response (actual m(pfst) per node) in validation cohort for the markers stratified according to image 
cytometric analysis. Left side of the alluvial plot depicts predicted response per node and right depicts 
actual response per node. Blue area connecting left to the right graph represent perfect match while red 
area represent mismatch in the response. The thickness of the color areas depicts the number of subjects. 
Kaplan-Meier curves for predicted response and actual response using the signature from image 
cytometric analysis showed an accuracy of 0.81 (95%CI: 0.71-0.89, accuracy P<0.001) fig. R2). 
Comparison of the C-index from immunohistochemistry with image cytometry showed marginal 
superiority and quality of single immunohistochemistry counts. 
 5 
 
Figure R2: Accuracy of prediction of the prognostic histological signature in the validation cohort 
on comparison to immune markers stratified according to image cytometry. Kaplan-Meier curve 
representing actual response obtained from immune markers stratified according to image cytometric 
analysis and predicted response derived from the prognostic histological signature generated from the 
ESPAC-Tplus cohort. Dotted lines depict the curves for predicted response whereas solid lines represent 
curves for actual response. The accuracy of prediction in the validation cohort using prognostic 
histological signature is given with 0.81 (95%CI: 0.71-0.89, accuracy P<0.001). P<0.05 is considered as 
significant. 
These results confirm that a prognostic signature is a powerful and robust tool in resected PDAC 
patients with good reproducibility, predictability and reliability. Furthermore, it confirmed that, 
irrespective of single immunohistochemistry on the consecutive sections or 
immunohistochemistry on a single section by multiplexing the prognostic histological signature 
has good reproducibility and robustness. These results indicate that tumor-infiltrating leukocytes 
and their response to stroma modulations are interdependent variables. 
We have not included the comparison of conventional image analysis and multiplexing cytometry 
in the manuscript as we believe that it does not directly impact on our story line and distracts the 
reader from our main findings. However, we found the data of great interest and wanted to share 
them with you. We hope that we have sufficiently addressed your concerns and we are grateful 
for your suggestions. 
 
Reviewer 1:  
This is a detailed histological study using resected PDAC samples from a retrospective cohort of 
patients, performed by a highly experienced and expert research team. Importantly, the focus in 
this study on characterising immune cell infiltration in PDAC stroma adds important knowledge 
to the field, while building upon previous literature related to stromal composition in terms of 
collagen and activated fibroblast/pancreatic stellate cells. The authors report identification of 
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specific leukocyte + stromal composition signatures that correlate with clinical outcome in terms 
of progression free survival. 
 
While the reported findings have the potential (if confirmed in validation studies) to identify 
patients who would do well or poorly with adjuvant treatment, it would be helpful if the following 
issues were addressed: 
 
1. Study subjects include a combination of patients actually treated with Gemcitabine or 5FU. It 
would be useful to indicate whether there were any differences in PFS per se between these two 
patient groups, to ensure that this would not confound the study results.  
We would like to apologize to the reviewer for not having been clearer in the manuscript 
regarding the treatment groups. The conclusion of the ESPAC3 trial was that, compared to the 
use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival or 
improved progression free survival in patients with resected pancreatic cancer. 5FU treatment is 
not superior to Gemcitabine treatment in the adjuvant setting of pancreatic cancer treatment. 
To entirely rule out your concerns we have now added data on the LIFETEST procedure for 
pairwise comparison of survival with different immune markers. In general, there was no 
statistical significant correlation between treatment arm and immune markers (suppl table S7). 
Also, pairwise comparison of survival factors to stroma composition did not reveal any statistical 
significant correlation (suppl table S8). Thus, we ruled out the influence of the treatment group 
on the signature. 
We have incorporated this results in the main manuscript on page number 14. 
Also was PFS defined as local (pancreatic) recurrence or the identification of malignant foci 
elsewhere? This issue may have relevance to the proposed pathogenetic role of type 2 
macrophages for example in pancreatic cancer progression. 
We thank the reviewer for raising this concern. In the ESPAC-1 and the ESPAC-3 trial, from 
which the ESPAC-Tplus TMAs are derived, progression-free survival was measured from the 
date of resection to the date of death from any cause or date of local tumor recurrence or 
metastases as documented by contrast enhanced CT. Patients remaining alive and without 
progression were censored at the date last seen alive1,2. In the ESPAC-3 trial, 63% of the 
patients developed local recurrence, metastases or both, 87% of which died1. On an individual 
patient level, we can’t discriminate from the trial data recorded who developed local recurrences 
or metastasis and patients’ numbers are too low in each subgroup to do meaningful statistics. 
We will try to answer your very relevant question on the role of M2 macrophages and their role 
of metastasis formation in a separate project.  
2. What was the inter-observer concordance between the two independent investigator scores 
for the various parameters tested? 
We would like to thank reviewer for his/her suggestion. We evaluated inter-observer 
concordance at two levels. We tested inter-rater reliability for H-score and observed an inter-
concordance coefficient (ICC), which is a measure of concordance for continuous variables, for 
picrosirius red/ fast green staining with 0.84 (95%CI: 0.82-0.85) (suppl fig. S2A). When we 
analyzed the inter-rater concordance for α-SMA H-Score, we found an ICC of 0.92 (95%CI: 
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0.92-0.93) (suppl fig. S2B). ICC in the range of 0.75-1.00 is associated with excellent inter-rater 
concordance3. 
Furthermore, we analyzed the inter-rater concordance for dichotomous high and low expression 
of picrosirius red/fast green and α-SMA. We determined Cohen’s Kappa, as a measure for inter-
rater concordance for categorical variables for picrosirius red/fast green with 0.75 (95%CI: 0.72-
0-77) and for α-SMA with 0.79 (95%CI: 0.77-0.81) (suppl fig. S2C-D). Cohen’s kappa in the 
range of 0.61-0.80 denotes good concordance4. Thus, overall we observed a good to excellent 
strength of agreement and inter-rater concordance. 
We have included these concordance data in the main manuscript on page number 7 and as 
figure in suppl fig.S2. 
3. While acknowledging the expertise of the pathologists involved in this study, it would be useful 
to include some details as to how intermediate staining was differentiated from low or high 
staining. While Supplementary Fig 4 provides examples of low and high expression, examples of 
'intermediate' expression are missing. 
We would like to thank the reviewer for bringing this concern to our attention. We have modified 
the figure and added intermediate expression denoted as “borderline expression” in suppl fig.1 
for illustrating purposes. 
We amended suppl figure 4 which is now incorporated as suppl fig.S3. 
4. The fibrolytic subtype of stroma (high alphaSMA high expression with low collagen 
expression) may indicate that the collagen secreted by activated fibroblasts is being actively 
degraded. In this context it may be of interest to assess the expression of matrix 
metalloproteinases/TIMPs in these samples. 
In order to answer the question above, we performed MMP7 immunohistochemistry staining in 
the validation cohort (n=93) and compared the staining intensity (H-Score) with respect to the 
stroma composition. We did not find any significant associations between MMP7 expression and 
type of stroma composition though the fibrolytic stroma type showed a trend to higher MMP7 
expression. In order to validate our data, we used the expression dataset (GSE71729) from 
Moffitt et al.5 and performed differential expression analysis in PDAC compared to normal 
pancreas. Selecting significantly altered genes with p<0.05, and stratification for the stroma 
subtypes based on expression of ACTA2 (α-SMA) and COL1A1 (collagen), the heatmap 
revealed differential expression of different collagen genes, matrix metalloproteases (MMPs) and 
the tissue inhibitors of metalloproteinases (TIMPs). However, we did not observe significant 
changes in MMP7 expression corresponding to stroma subtypes. MMP7 expression is always 
accompanied by dysregulated TIMP1 expression and is required for MMP7 activity6. We 
detected upregulated TIMP1 expression in the fibrolytic stroma compartment group. 
It has been reported that pancreatic stellate cells are able to secrete different MMPs and their 
activities regulate the degradation as well as the synthesis of extracellular matrix proteins7 .In 
order to substantiate these claim, we performed multiplexing followed by image cytometric 
analysis. We found a significant increase in MMP7+ cells in the fibrolytic stroma compartment. 
Furthermore, we found a significant increment in MMP7+ cells in α-SMA+ gated cells. Thus, our 
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results support the hypothesis that higher MMP7 expression in fibrolytic stroma are associated 
with collagen degradation. 
We have included these data for review purposes only as we think, though very interesting 
indeed, it detracts the reader from our initial story line and the manuscript is already to lengthy 
with regard to the author guidelines of Gastroenterology. We hope that you can agree on this.  
 
Figure R3: High MMP7 expression in fibrolytic stroma compartment patients. (a) Boxplot showing 
MMP7 expression in the validation cohort stratified according to the stroma subtype . (b) Heatmap 
showing differentially expressed matrix metalloproteases (MMPs) and tissue inhibitors of matrix 
metalloproteases (TIMPs) genes from GSE71729 expression dataset. (c) Boxplot illustrating expression of 
MMP7 and TIMP1 genes in different stromal compartment. (d) Boxplot revealing percent of MMP7+ cells 
in different stroma subtypes inform the validation cohort analyzed by image cytometry following 
multiplexing. (e) Boxplot showing percent of MMP7+ cells in α-SMA+ gated cells in different stroma 
subtypes in the validation cohort. *p<0.05 considered statistically significant. 
Reviewer 2:  
The authors investigated immune microenvironment and stromal composition in resectable 
pancreatic cancer from the ESPAC-1 and 3 cohorts. They showed the evidence of a prognostic 
signature incorporating leukocytic subpopulations and stromal composition to stratify PDAC 
patients with respect to PFS. They provide prognostic tree for PFS and classified the PDAC 
patients into seven subtypes based on expression of CD3, CD4, CD8, CD68, CD206, and 
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stromal composition. Patients with CD3highCD206high signature had the best PFS whereas 
patients with CD3lowCD8lowCD68high signature showed the worst PFS. They concluded that 
their prognostic signature can provide important prognostic information for PDAC patients with 
further validation study. This is an interesting study but there are several concerns that need 
attention: 
1. This article provides a discrete-time survival tree for PFS using immune and stromal 
signature. It seems unclear why these two factors were chosen whereas there were much more 
powerful factors such as lymphatic node invasion and postoperative CA19-9 for predicting PDAC 
prognosis in this study. Furthermore, there is no other comparative index in this manuscript to 
compare the performance of stratification into homogenous prognostic subgroups to show the 
superiority of their signature. 
We thank the reviewer for the concern and suggestion. He raises a very valuable point. We 
initially selected immune markers and stroma subtypes that demonstrated a statistically 
significant effect on progression free survival based on a multivariate analysis adjusted for 
independent prognostic variables such as the ones mentioned by the reviewer. (table 4, suppl 
table 9). 
We have now performed nonparametric testing for competing risks using random forest 
iterations analysis for categorical variables such as stage, resection margin, postOpCA19.9 
(dichotomized based on median), lymph node invasion and local invasion and used it as a 
reference signature. We determined that only postOpCA19.9 and Lymph node invasion 
significantly influence PFS, however with a lower strength of VIMPs (suppl fig.S8A). Based on 
these results, we performed multivariate recursive partitioning for discrete-time survival tree for 
PFS, which lead to the three-terminal nodal prognostic signature. The relative error of the 
signature was 0.07 (x-error 0.01) (suppl fig.S8A). When we compared our histological signature 
to the reference signature for the prediction, using ROC survival analysis, we observed an AUC 
of the histological signature of 0.71(concordance: 0.60 ± 0.01) compared to 0.63 (concordance: 
0.63 ± 0.01) for the reference signature suppl fig.S8A). This lead us to conclude that the 
histological signature performed better if compared to the reference signature suggested by the 
reviewer. 
We have included this data in the main manuscript on page number 16 and as figure in suppl 
fig.S8. 
2. The authors concluded that their prognostic signature can provide important information for 
patients after PDAC resection with the implication of therapeutic stratification and postoperative 
management. However, in this study, pairwise comparisons of variations of immune cell 
subpopulation and stromal composition with respect to the therapeutic arm did not show any 
statistically significant association with PFS or OS, which limits the novelty and enthusiasm for 
this work. 
We would like to apologize to the reviewer for not having been clearer in our conclusion. We 
entirely agree we developed a prognostic signature which is currently not predictive. We took 
your concern seriously and have amended our discussion. 
We amended our conclusion and now it reads on page 21 as: 
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When thinking about adjuvant immunomodulatory therapy such as using M2-macrophage 
inhibitors or JAK inhibitors such signatures could become the basis for stratification.  
3. In page 10 line 7, 8 and line 22, "hazard ratio of 0.78 (95%CI 1.02- 1.58, p=0.03)" and "0.69 
(95%CI 1.10-1.88)"seems strange because these HRs are not in their 95%CI. This must be 
addressed. 
We thank the reviewer for bringing this to our notice. It was a typographical error.  
We have corrected it and now it read as "hazard ratio of 0.78 (95%CI 0.63- 0.98, p=0.03)" and 
"0.69 (95%CI 0.52-0.90)". 
4. ESPAC is the study for resectable pancreatic head cancer but the table demonstrates there 
were 20 distal pancreatectomy cases. It is difficult to imagine the situation where the distal 
pancreatectomy was performed for pancreatic head cancer with respect to anatomy. 
We would like to thank the reviewer for this concern. In the ESPAC trial, patients were eligible to 
participate in the trial if they had undergone complete macroscopic (R0 or R1) resection for ductal 
adenocarcinoma of the pancreas with histological confirmation and with no evidence of 
malignant ascites, peritoneal metastasis, or spread to the liver or other distant abdominal or 
extra-abdominal organs. The type and extent of resection was determined using an established 
international classification1. In summary, the localization of the primary was not an exclusion 
criteria as long it was resectable and no systemic spread was detected at time of diagnosis. The 
original publication is cited as reference 1 for detailed information on the study protocol. 
5. In table 3, the multivariate analysis was performed using selected variables. It seems unclear 
why authors chose only immune and stromal status whereas lymph node invasion, resection 
margin, and post-operative serum CA19-9 have high impact to PFS in univariate analysis. 
We would like to thank the reviewer for bringing this to our attention and from a clinician 
perspective his/her concern is very relevant. We preformed multivariate analysis to obtain a Cox 
proportional hazard model with variables consisting of stroma composition CD3, CD4, CD8, 
CD68, CD206 expression, lymph node invasion, resection margin and tumor stage (suppl table 
S9). We determined an AIC (Akaike information criterion) for this model with 2851.15 in 
comparison to the AIC for a model involving only stroma and immune markers of 2792.91. Thus, 
we conclude that based on Akaike information criterion (AIC), having lower AIC, the model 
described in table 4 is superior to the model described in suppl table S9.  
Furthermore, after adjusting for independent variables, the model including lymph node invasion, 
resection margin and tumor stage did not demonstrate a statistically significant impact on 
progression free survival. 
We have included this data in main manuscript on page number 15 and as suppl table S9. 
 6. It might be better that Figure 1D is treated as a table. 
We thank the reviewer for his/her suggestion.  
We have amended Figure 1 and made a table which is now incorporated as table 2. 
7. For OS multivariate analysis, the different way of selecting variables from PFS analysis was 
employed. The explanation for it might be required. 
 11 
We would like to apologize to the reviewer for not having provided this explanation. The variable 
selection in multivariate recursive partitioning for discrete-time survival tree for the overall 
survival model is based on random forest iterations and is an unbiased selection. Also, the 
multivariate recursive partitioning for discrete-time survival tree model is based on prognostic 
strength of individual biomarkers taken into consideration (table 4 and suppl table S3). As the 
prognostic strength is different for PFS and OS, we determined a different model for OS. 
We incorporated the description in legends of suppl fig.S7. 
Minor comments: 
1. In Supplementary Table S2, the spelling of "fibrogenic" in second column and first row should 
be fixed. 
We thank the reviewer for pointing out this typographical error.  
We have amended the table which is now suppl table S4. 
 2. In Supplementary Table S5, the spelling of "fibrogenic" in second column and first row should 
be fixed. 
We thank reviewer for pointing this typographical error.  
We have amended the table which is now suppl table S5. 
3. In Supplementary Figure 3B, "m(pfst)" in node 11 should be changed as m(st). 
We thank the reviewer for bringing this to our notice.  
We have corrected it and now it reads as m(st). 
  
 12 
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Glossary 1 
 2 
Term Explanation 
Immunohistochemistry 
(IHC): 
immunostaining on the sections obtained from formalin 
fixed paraffin embedded tissue-blocks or tissue 
microarrays. 
Multiplex 
immunostaining 
consecutive multiple immunostaining followed by 
destaining on sections obtained from paraffin embedded 
histoblocks or tissue microarrays (TMA). 
Intratumoral cells 
(ITC) 
isolated cells from the digestion of PDAC resection 
specimen. 
Image cytometry colocalization analysis and quantification of immune 
markers after multiplex immunostaining. 
Cytoblocks immunostaining on the sections obtained from paraffin 
embedded isolated intratumoral cells. 
Cytospins immunostaining on slides obtained from cytospining of 
isolated intratumoral cells. 
Actual response actual median progression free survival of patients 
recruited in the validation cohort with respect to the 
immune marker subcohort. 
Predicted response predicted median progression free survival of patients 
recruited in the validation cohort with respect to the 
immune marker subcohort derived from ESPAC-Tplus 
cohort. 
VIMP Variable of importance (VIMP) depicting the weightage of 
the categorical variable in random forest iterations. 
Terminal node binary split criteria in a decision tree using random forest 
iterations are called node. Terminal nodes are prognostic 
subcohorts derived from the recursive partitioning for 
discrete time survival tree analysis. 
 3 
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Abstract:  1 
Background & Aims: Changes to the microenvironment of pancreatic ductal 2 
adenocarcinomas (PDACs) have been associated with poor outcomes of patients. We 3 
studied the associations between composition of the pancreatic stroma (fibrogenic, inert, 4 
dormant, or fibrolytic stroma) and infiltration by inflammatory cells and times of progression-5 
free survival (PFS) of patients with PDACs after resection. 6 
Methods: We obtained 1824 tissue microarray specimens from 385 patients included in the 7 
European Study Group for Pancreatic Cancer trial 1 and 3 and performed 8 
immunohistochemistry to detect alpha smooth muscle actin, type 1 collagen, CD3, CD4, 9 
CD8, CD68, CD206, and neutrophils. Tumors that expressed high and low levels of these 10 
markers were compared with patient outcomes using Kaplan-Meier curves and multivariable 11 
recursive partitioning for discrete-time survival tree analysis. Prognostic index was delineated 12 
by a multivariable Cox-proportional-hazards-model of immune cell and stromal markers and 13 
PFS. 14 
Findings were validated using 279 tissue microarray specimens from 93 patients in a 15 
separate cohort. 16 
Results: Levels of CD3, CD4, CD8, CD68, and CD206 were independently associated with 17 
tumor recurrence. Recursive partitioning for discrete-time survival tree analysis identified a 18 
high level of CD3 as the strongest independent predictor for longer PFS. Tumors with levels 19 
of CD3 and high levels of CD206 associated with a median PFS time of 16.6 months and a 20 
median prognostic index of –0.32 (95% CI, –0.35 to –0.31), whereas tumors with low level of 21 
CD3 cell and low level of CD8 and high level of CD68 associated with a median PFS time of 22 
7.9 month and a prognostic index of 0.32 (95% CI, 0.050–0.32)—we called these patterns 23 
histologic signatures. 24 
Stroma composition, when unassociated with inflammatory cell markers, did not associate 25 
significantly with PFS. In the validation cohort, the histologic signature resulted in an error 26 
matrix accuracy of predicted response of 0.75 (95% CI, 0.64–0.83; accuracy P<.001). 27 
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Conclusions: In an analysis of PDAC tissue microarray specimens, we identified and 1 
validated a histologic signature, based on leukocyte and stromal factors, that associates with 2 
PFS times of patients with resected PDACs. Immune cells might affect the composition of the 3 
pancreatic stroma to affect progression of PDAC. These findings provide new insights into 4 
the immune response to PDAC.  5 
Key words: ESPAC, pancreatic cancer, histologic analysis, prognostic factor  6 
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Introduction: 1 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and 2 
burdened with a 5-year survival rate of around 6%1,2. Multiple factors are considered to be 3 
responsible for this dismal prognosis but essentially involve two problems: late diagnosis and 4 
profound treatment resistance - combined with lack of personalized treatment options3,4. 5 
PDAC is known for its desmoplastic stroma reaction comprised of activated myofibroblasts, 6 
leukocytes and extracellular matrix5. PDAC desmoplasia is thought to confer biological 7 
aggressiveness6, however, recent evidence from animal models demonstrated that an 8 
absence of desmoplasia resulted in an even more undifferentiated and aggressive tumor 9 
phenotype5,7,8, suggesting that stroma composition influences cancer biology in a more 10 
complex manner. Preliminary data suggest a correlation between poorer clinical outcome 11 
and the composition and quantity of tumor infiltrating immune cells as well as tumor 12 
associated myofibroblasts, resulting in a weaker adaptive immune response in PDAC9,10. Not 13 
surprisingly several attempts have been made to evaluate the prognostic significance of 14 
tumor-infiltrating leukocytes in a variety of human non-pancreatic cancers at the level of 15 
genomics, transcriptomics and histology11. Here, prognostic significance of a prominent 16 
overall leukocyte infiltration has been shown to be  associated with increased survival11. 17 
However, to understand the complexity and plasticity of stroma formation in pancreatic 18 
cancer and its associated leukocytes, a combination of approaches with supervised 19 
predictors of disease progression is required to determine prognostic signatures. Such an 20 
approach could reveal signatures for risk stratification and will be hypothesis-generating with 21 
regard to underlying biological mechanisms and potential targets12.  22 
In order to generate a prognostic landscape of infiltrating immune cells and stromal 23 
composition across pancreatic cancer we investigated T-lymphocytes (CD3, CD4/CD8), 24 
tumor associated macrophages, alternatively activated macrophages and neutrophils along 25 
with their associated stromal composition and compared those to progression free survival 26 
data of the patients.  27 
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Promising prognostic biomarkers did not achieve clinical significance and some explanation 1 
are the use of retrospectively collected uncontrolled material with too small a sample size, 2 
non-standardized assays and inappropriate or misleading statistical analyses. To overcome 3 
these limitations and to minimize the bias we not only followed the REMARK guidelines4 but 4 
used data and tissue from a prospective randomized controlled trial (ESPAC-Tplus) on 5 
adjuvant treatment of pancreatic cancer conducted by the European Study group for 6 
Pancreatic Cancer. We delineated a prognostic signature based on organ-based leukocyte 7 
subpopulations and stromal composition which identifies cancer subtypes and predicts 8 
progression free survival.  9 
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Materials and Methods: 1 
Study Design 2 
The translational ESPAC-T studies received ethical committee approval for characterization 3 
of tumor markers for chemotherapy from the Liverpool (Adult) Research Ethics Committee 4 
(07/H1005/87). Use of Good Clinical Practice standard operating procedures13 ensures a full 5 
audit trail and prevents access to outcome data by pathologists and laboratory researchers. 6 
After resection for pancreatic ductal adenocarcinoma, patients in the ESPAC-3 study were 7 
randomized to receive either 5FU/folinic acid or gemcitabine. ESPAC-3 was analyzed on an 8 
intention to treat basis, but for the ESPAC-T study patients, arms were selected for inclusion 9 
only if treatment was actually received. This study was conducted and reported in 10 
accordance with the REMARK criteria4,14.  11 
Tissue Microarray Manufacture for identification and validation cohort 12 
The arrays from ESPAC-Tplus were reported previously4. TMAs for the independent 13 
validation cohort (n=93) were derived from a prospective cohort recruited at the university of 14 
Munich carried out according to the recommendations of the local ethics committee of the 15 
Medical Faculty of the University of Munich, Germany. TMA generation was reported 16 
previously15. 17 
Single and multiplex immunostaining and quantification of TMA cores  18 
Detailed information of the single and multiplex immunostaining and antibodies are provided 19 
in the supplemental materials and methods section. Immunohistochemistry using DAB 20 
complex conjugation techniques (Vector Laboratories Ltd., Peterborough, UK) were 21 
performed as described earlier16. Chloracetate esterase staining for detection of neutrophils 22 
infiltration was performed using Naphthol AS-D chloracetate (specific esterase) kit (Sigma-23 
Aldrich) as per manufacturer’s instruction. Specific collagen staining was performed on each 24 
core using Picrosirius Red-Fast Green staining solution (0.1% Direct Red 80 and 0.1% Fast 25 
Green FCF in aqueous picric acid). Multiplex immunostaining for the validation cohort was 26 
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performed as described previously with some modifications17. Details of multiplex 1 
immunostaining and quantification are provided in supplementary materials and methods. 2 
All the staining cores were scored by two investigators independently blinded to treatment 3 
group when scoring, as well as blinded to patient outcomes throughout the study. 4 
Quantification was undertaken for α-SMA according to the intensity of staining in the tumor 5 
core ranked from 0 to 3 (0= no staining, 1= low staining, 2= intermediate staining and 3= high 6 
staining) and the percentage of area stained was calculated using an algorithm developed for 7 
NIH ImageJ software (suppl fig.S1A). H-Scores were calculated for each core by multiplying 8 
intensity score by the percentage of core staining and a median H-Score calculated for all 9 
cores from each patient. Collagen quantification was performed by Picrosirius Red 10 
(Collagen) and Fast Green (rest of the tissue) according to the intensity of staining in the 11 
tumor core ranked from 0 to 3 (0= no staining, 1= low staining, 2= intermediate staining and 12 
3= high staining) and the percentage of area stained was calculated using an algorithm 13 
developed for the NIH software ImageJ. H-Scores were calculated for each core by 14 
multiplying the intensity score by the percentage of core staining and a median H-Score 15 
calculated for all cores from each patient individually for Picrosirius Red and Fast Green. 16 
Final H-score for collagen staining was calculated as a ratio of Picrosirius Red to that of Fast 17 
Green. Inter-rater reliability for the H-score and the observed inter-concordance coefficient 18 
(ICC) for picrosirius red/ fast green staining was 0.84 (95%CI: 0.82-0.85) and for α-SMA 0.92 19 
(95%CI: 0.92-0.93) (suppl fig. S2A-B). The leukocyte infiltration was determined as number 20 
of cells/mm2 (suppl fig. S3) using an algorithm developed for NIH software ImageJ (suppl 21 
fig. S1B). The cut-off for each marker was calculated using cut-off finder with the 22 
incorporation of the Log-rank method described earlier18. All the cut-offs used for 23 
classification of markers to dichotomize low and high expression are described in the suppl 24 
table S1, with representative images in suppl fig.S3. Stromal composition by means of 25 
expression of α-SMA/collagen was divided as described previously as dormant (low α-26 
SMA/high collagen expression), inert (low α-SMA/low collagen expression), fibrogenic (high 27 
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α-SMA/high collagen expression) and fibrolytic (high α-SMA/low collagen expression) 1 
stroma10,19.  2 
IHC staining evaluation in comparison to flow cytometry  3 
From 10 PDAC patients, freshly resected tumor tissue was processed for paraffin tissue-4 
block embedding and primary cell isolation. Moreover, EDTA blood was provided for 5 
assessment of peripheral blood derived monocytes cells (PBMCs); the detailed isolation 6 
procedure is given in the supplemental material and method section. The PDAC tissue 7 
samples were double-coded and corresponding data were provided by the Biobank of the 8 
Department of General, Visceral and Transplantation Surgery, University Hospital, LMU 9 
Munich, Germany, under the administration of the Human Tissue and Cell Research (HTCR) 10 
Foundation. The framework of HTCR Foundation20, which includes obtaining written informed 11 
consent from all donors, has been approved by the ethics commission (approval number 12 
025-12) of the Faculty of Medicine, LMU Munich, Germany as well as by the Bavarian State 13 
Medical Association, Germany (approval number 11142). The leukocyte cell population from 14 
tumor tissue and blood samples was analyzed by flow cytometry (fluorescence-activated cell 15 
sorting, FACS). The intratumoral leukocytes determined by FACS revealed a strong positive 16 
correlation to immunohistochemical staining on tissue-blocks (solid black square in the 17 
correlogram in suppl fig.S4). 18 
Statistical Analysis 19 
For all analyses, the sample size was limited to appropriate cases with full data; no 20 
imputation was performed to estimate missing clinical information. Survival from the date of 21 
resection was analyzed by the method of Kaplan-Meier; differences between groups were 22 
assessed using the Mantel-Cox log rank test. Survival was either to death from cancer 23 
(overall survival time, OS) or to recurrence as assessed by computer tomography or 24 
ultrasound or through histology/cytology (progression free survival time, PFS). Multivariate 25 
Cox regression analyses were used to adjust for the progression free survival effect by all 26 
important prognostic variables on a complete case basis. Covariates were included in the 27 
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multivariable model using forward stepwise regression approach based on the Akaike 1 
Information Criterion if they had an unadjusted log-rank significance of P<0.25. When more 2 
than two survival cohorts were compared, the log-rank test was used to assess global 3 
differences in survival. Box-and-whisker plots show median, quartiles, and range of 4 
continuous data to demonstrate the variability of data and the degree of normality. All 5 
analyses were carried out using R 2.1.0 (http://cran.r-project.org/src/base/R-2/R-2.1.0.tar.gz) 6 
and R-studio 1.0.153 (https://github.com/rstudio/rstudio/tarball/v1.0.153). A two-sided 7 
significance of P<0.05 was used throughout. Detailed methodology is described in 8 
supplementary materials and methods. 9 
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Results 1 
Patients and tissue samples 2 
Tissue microarrays (TMA) from 403 patients resected for pancreatic ductal adenocarcinoma 3 
(for detail see CONSORT diagram in figure 1A) were employed. As expected and previously 4 
reported, there was no significant difference with regard to treatment with gemcitabine or 5-5 
flourouracil/folinic acid for progression free survival (PFS) or overall survival (OS) within the 6 
trial and our cohort21. Furthermore, treatment regimens did not impact on PFS with regard to 7 
specific prognostic signatures delineated within this manuscript (see suppl table S7-S8). 8 
Demographics, surgery and pathology features of the patients included are summarized in 9 
table 1. Within the present study, we mainly focus on PFS as primary outcome as we 10 
controlled for the effect of adjuvant chemotherapy by randomization.  11 
Composition of leukocyte infiltrate and its prognostics association 12 
To systematically map compositional differences of different leukocyte subsets in the tumor 13 
microenvironment and their influence on PFS, we performed immunohistochemical analysis 14 
of CD3, CD4, CD8, CD68, CD206 and chloracetate esterase in TMAs and quantified 15 
leukocyte subpopulations (figure 1B).  16 
The density of tumor infiltrating T-lymphocytes has been proposed as an independent 17 
predictor of outcome in solid tumors22–24. In line with these observations, we performed 18 
survival analyses for high and low levels of CD3 expression and observed a significant 19 
association of high CD3 expression with significantly increased PFS; median PFS 14.32 20 
months (95%CI 12.74-17.28) compared to low CD3 expression; median PFS 11.03 months 21 
(95%CI 9.69-12.45), resulting in a hazard ratio of 0.65 (95%CI 0.53-0.80, p<0.0001) (figure 22 
1C, table 2). To investigate the associations of CD4+ T-cells with PFS we performed Kaplan-23 
Meier survival analyses for dichotomized CD4 low and high counts, which only marginally 24 
influenced PFS (median PFS 12.81 (95%CI 11.72-14.91) for high CD4 expression vs 10.87 25 
(95%CI 9.23-14.91) for low CD4 expression, p=0.03) (table 2). The importance of tumor 26 
infiltrating lymphocytes, particularly antitumor cytotoxic T-cell (CD8 positive), has been 27 
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underlined by their prognostic associations in several human cancers25. We sought to 1 
determine the influence of cytotoxic T-cell infiltration on PFS. Kaplan-Meier survival analysis 2 
revealed a trend towards higher cytotoxic T-cell counts in the tumor with favorable PFS 3 
resulting in a hazard ratio of 0.78 (95%CI 0.63-0.98, p=0.03) (table 2) which supports 4 
previous studies25. In short, absence of infiltrating T-lymphocytes is associated with 5 
decreased PFS. 6 
Next, we evaluated the density of infiltrating CD68 expressing tumor associated 7 
macrophages (TAMs) and performed Kaplan-Meier survival analysis with regard to CD68 8 
expression and observed higher counts of TAMs (CD68) associated with improved PFS; 9 
median PFS of 13.30 months (95%CI 11.92-16.39) compared to patients with low infiltration 10 
median PFS 11.72 months (95%CI 9.52-13.76)) giving a hazard ratio of 0.78 (95%CI 0.62-11 
0.98, p=0.02) (table 2).  12 
There is evidence suggesting TAMs are reprogrammed from polarized activated 13 
macrophages (ΦM1) to alternatively activated macrophages (ΦM2) shifting the 14 
immunoregulatory response and affecting microenvironment26. We quantified the staining of 15 
alternatively activated macrophages (ΦM2, CD206+), and dichotomized distribution of 16 
CD206 counts. It revealed a significant association of high CD206 count with a median PFS 17 
of 13.76 months (95%CI 11.99-15.63) compared to a median PFS of 10.28 months (95%CI 18 
8.60-12.74) in the low CD206 count group, giving a hazard ratio of 0.69 (95%CI 0.52-0.90) 19 
(table 2). Our dataset revealed that differential tumor infiltration of ΦM1 with a concomitant 20 
increase in ΦM2 correlates to an increase in PFS. 21 
Circulating leukocytes, such as neutrophils are known to contribute to the tumor 22 
microenvironment11. Several lines of evidence indicate that a high density of neutrophils 23 
promotes tumor growth and metastasis27. Density of neutrophil infiltration on PFS or OS did 24 
not show a significant correlation (table 2). 25 
  26 
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Identification of different subtypes of stromal composition 1 
The key to understanding the role of the stroma is its composition. We investigated the 2 
expression pattern of α-SMA and collagen in resected PDAC with respect to PFS. 3 
Unexpectedly, α-SMA as well as collagen expression alone were not associated with 4 
extensive stroma formation or PFS (suppl fig.5A-B). Thus, we categorized the stroma on 5 
the basis of differential expression of α-SMA and collagen I as previously established by 6 
Erkan and colleagues10 as fibrogenic (high α-SMA/high collagen expression), inert (low α-7 
SMA/low collagen expression), dormant (low α-SMA/high collagen expression) and fibrolytic 8 
stroma (high α-SMA/low collagen expression) (figure 2A, representative images). The 9 
overall median PFS of the cohort was 12.71 months (95% CI 11.63-14.19) with a median 10 
PFS for inert stroma of 13.76 months (95%CI 10.87-16.65), with dormant stroma of 12.69 11 
months (95% CI 9.69-16.06), with fibrogenic stroma of 14.09 months (95% CI 11.99-20.10) 12 
and with fibrolytic stroma of 11.05 months (95%CI 8.87-12.74), 2=7.09, p=0.06 (figure 2B). 13 
The difference between fibrolytic in comparison to fibrogenic stroma was significant with a 14 
hazard ratio of 1.48 (95%CI 1.08-2.01, p=0.01) (suppl fig.S5C; OS: suppl. Fig.S6). Taken 15 
together, these results indicate that categorization of stromal composition considering 16 
differential α-SMA and collagen expression correlates to PFS. 17 
The impact of the stromal compartment on T-lymphocytes migration orchestrates the 18 
hierarchy of interactions between immune cells and tumor cells28. This suggests that the 19 
tumor microenvironment regulates the immune response and vice versa. In order to identify 20 
the connection between stromal subtype and immune infiltration, we performed comparative 21 
correlation analyses. It revealed dominant clusters each for a TH1 driven immune response 22 
characterised by abundant CD3, CD4, CD206 expression and for pro-inflammatory 23 
modulators such as CD8, CD68 and neutrophils in respect to fibrogenic and dormant stroma. 24 
Inert and fibrolytic stroma showed the two dominant clusters for CD4, CD206, CD3, CD8, 25 
CD68 and neutrophils (figure 2C).  26 
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To ascertain the influence of immune infitration in modulating stromal composition, we 1 
analyzed distribution of immune infitrates in different stromal subtypes and found differential 2 
distribution of immune cells infitrates with respect to stromal subtypes (figure 2D). Fibrolytic 3 
stroma has more abundant CD206+ ΦM2 with reduced CD8+ T-cells and CD68+ ΦM1 4 
suggesting an immunosuppressive tumor microenvironment while fibrogenic stroma 5 
associated with increased PFS was more abundant for CD8 T-cells and CD68 positive 6 
macrophages (figure 2D).  7 
We analyzed the influence of low and high expression of immune infiltrates on PFS with 8 
respect to stromal subtypes (table 3). We found that CD3 dichotomization predicts 9 
differential PFS in fibrogenic and fibrolytic stratified patients, whereas CD4 dichotomization 10 
predicts differential PFS in fibrogenic stroma. CD68 dichotomization predicts differential PFS 11 
in inert stratified patients whereas CD206 dichotomization predict differential PFS in dormant 12 
stratified patients. Taken together, subtypes of stroma not only differ in α-SMA and collagen-13 
I expression but show a distinctly different pattern of leukocytes subpopulation depending on 14 
stroma subtype which then predicts PFS.  15 
Contingency testing of immune infiltrate and stromal subtypes with other clinical and tumor 16 
characteristics (suppl. Table S2) did not reveal any statistically significant associations. 17 
Contribution of infiltrating leukocytes in defining stromal composition 18 
To complement our immune cell marker-centered survival analysis, we compiled 19 
combinatorial prognostic associations for immune infiltrates (CD3+ T-cells, CD4+ T-cells, 20 
cytotoxic T-cells, ΦM1, ΦM2, and neutrophils). We performed a univariate analysis with PFS 21 
as endpoint and observed considerable variations between infiltrating immune cell 22 
subpopulations and survival (table 4). Univariate analysis of the independent variables: 23 
lymph node invasion, resection margin status, local invasion, maximum tumor diameter and 24 
post-operative CA19.9, showed significant associations with PFS in the complete cohort 25 
(table 4). Univariate analysis and multivariable analysis with overall survival factors showed 26 
similar results (suppl. table S3).  27 
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Pairwise comparisons of variations of immune cell subpopulations with respect to stromal 1 
composition did not show significant associations with PFS or OS (suppl. table S4). A 2 
positive resection margin increased the risk of local recurrence. Pairwise comparison of 3 
resection margin and immune infiltrates to investigate the influence on PFS or OS was 4 
performed. We found a significant association of high expression of immune cells in negative 5 
resection margin stratified patients (suppl. table S5-6). Pairwise PFS as well as OS survival 6 
comparisons of variations of immune cell subpopulation and stromal composition with 7 
respect to the therapeutic arm did not show any statistically significant association with PFS 8 
or OS (suppl. table S7-S8).  9 
A composite prognostic signature for predicting progression free survival in PDAC 10 
Low expression of T-lymphocytes and tumor-associated macrophages are associated with 11 
worse prognosis and our data on fibrolytic stroma suggest that activated fibroblasts are at 12 
least partially involved in the poor outcome of these patients. We thus hypothesized that the 13 
differential expression pattern of high leukocyte subpopulations may characterize a favorable 14 
stroma composition. Analyses presented above were all dependent on tumor stratification 15 
and the set-up of predefined groups. In order to evaluate this, we performed a non-16 
parametric approach for competing risks using random survival forests and used it for 17 
selecting progression-specific variables and for estimating the cumulative incidence function. 18 
Progression-specific variables of importance (VIMP) and minimal depth variable selection 19 
were used to identify variables specific for all events. We found that, except for neutrophils 20 
count, all variables (CD3, CD4, CD8, CD68, CD206 and stroma) significantly influenced PFS. 21 
CD3 expression has the maximum influence on PFS with a VIMP of 2.63 and a minimum 22 
depth of 1.15 followed by CD8 and CD206 (figure 3A). 23 
To establish a prognostic signature combining leukocyte infiltration and stroma composition, 24 
we developed an algorithm evaluating the presence and prognostic strength of a signature in 25 
resected pancreatic cancer. Recursive-partitioning for discrete-time survival-tree-analysis 26 
using PFS as predictive endpoint delineated a regression tree according to prognostic 27 
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variables that classified patients into homogeneous subsets by PFS (figure 3B). We 1 
detected seven terminal nodes (subcohorts) characterizing a prognostic signature. The 2 
predicted prognostic signature for patients harboring CD3highCD206high signature was 3 
associated with a median PFS time of 16.60 (95%CI 13.80-23.80) compared to patients 4 
harboring CD3lowCD8lowCD68high showing the worst PFS of 6.27 months (7.95 months 5 
(95%CI 3.91-14.56). Our analyses support a complex, multi-marker signature model of 6 
stromal compartments in PDAC, which may explain why single predefined marker analyses 7 
have yielded mixed results. 8 
We extended the analysis by separately testing the association between the prognostic 9 
signature and clinical outcome in a multivariable Cox proportional hazards model integrating 10 
variables for random forest analysis (table 4). After adjustment for infiltrating immune cell 11 
subpopulations, multivariable analysis confirmed CD3, CD8 and CD206 expression status as 12 
significantly associated with PFS (CD3, p=0.005, CD8, p=0.02 and CD206, p=0.004). We 13 
compared this multivariate analysis obtained from a Cox proportional hazard model with a 14 
multivariate analysis again using the Cox proportional hazard model including stromal 15 
composition, CD3, CD4, CD8, CD68 and CD206 expression, along with known relevant risk 16 
factors such as lymph node invasion, resection margin and tumor stage (suppl table S9). 17 
Based on Akaike’s information criterion (AIC) described in table 4, a model only taking into 18 
account stroma composition and immune infiltrate had a higher predictive strength than a 19 
model including clinical parameters as described in suppl table S9. Furthermore, after 20 
adjusting for independent variables the model including clinical parameters did not predict 21 
progression free survival. We integrated the prognostic signature incorporating immune 22 
infiltrates and stromal composition delineating a relative prognostic index from a multivariable 23 
Cox-proportional-hazards-model of prognostic factors and PFS. The waterfall plot of our 24 
relative prognostic indices of terminal nodes (patients’ subgroups) depicts the relevance of 25 
this approach. Of note, the prognostic index for patients harboring CD3highCD206high 26 
signature depicts a higher probability of prolonged PFS than patients harboring a 27 
CD3lowCD8lowCD68high signature (figure 3C, overall survival: suppl fig S7). Nonparametric 28 
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testing for competing risks using random forest iterations analysis for risk factors such as 1 
stage, resection margin, postOpCA19.9 (dichotomized based on median), lymph node 2 
invasion and local invasion used as a reference signature. Immune marker-based signature 3 
(AUC=0.71) fared better compared to reference signature (AUC=0.63) (suppl fig.S8). 4 
Independent validation of the prognostic signature derived from the ESPAC-Tplus 5 
cohort 6 
To validate our prognostic histological signature, we used an independent cohort consisting 7 
of 93 patients (CONSORT diagram in suppl fig.S9). We performed immunostaining of CD3, 8 
CD4, CD8, CD68, CD206, MPO, α-SMA and collagen, followed by multiplex immunostaining 9 
analysis. The demographics of patients are shown in suppl. table S10. The median overall 10 
survival (OS) and progression free survival (PFS) of the validation cohort was 33.53 months 11 
(95%CI: 27.39-39.87) and 16.79 (95%CI: 12.55-20.35), respectively. As depicted in suppl 12 
fig.S10C our results on individual markers and their correlation from the identification cohort 13 
are replicated in the validation cohort except for the CD68 count and its correlation to PFS 14 
(suppl fig.S10C). Results of univariate and multivariate analysis of prognostic factors in the 15 
validation cohort are shown in suppl table S11-12 and again validate our data from the 16 
identification study.  When we tested the prognostic histological signature in the validation 17 
cohort the predicted response as defined by nodal localization as well as the accuracy of the 18 
predicted median progression free survival (predicted m(pfst) per subcohort) in comparison 19 
with the actual response (actual m(pfst) per subcohort) was in good concordance and good 20 
predictability as depicted by the alluvial plot (figure 3D). The prediction analysis revealed a 21 
Cohen’s Kappa with 0.69 and Harrell’s C-index with 0.60. In conclusion, the signature 22 
showed good reproducibility and robustness in the validation cohort.  23 
We substantiated our finding by plotting Kaplan-Meier curves of predicted response and 24 
actual response of the validation cohort (suppl fig.S10D). We determined an accuracy of 25 
0.75 (95%CI: 0.64-0.83, accuracy P<0.001). We detected a positive correlation between 26 
predicted response and actual response with R=0.62 and P<0.001. In conclusion, the 27 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Mahajan et al Prognostic signature based on interaction of immune cell infiltration with stromal composition in PDAC Gastroenterology 2018 
18 
 
validation cohort confirmed the prognostic value of the biomarker signature established in the 1 
ESPAC cohort (identification cohort).   2 
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Discussion: 1 
In this article, we demonstrate that the immune microenvironment in PDAC cancer can be of 2 
prognostic value for PFS after resection. Moreover, we provide evidence of a prognostic 3 
signature incorporating leukocytes subpopulations and stromal composition to stratify 4 
patients in respect to PFS. Subtypes of stroma not only differ in a-SMA and collagen I 5 
expression but show a distinctly different pattern of leukocyte subpopulation depending on 6 
stroma subtypes. As the prognostic signatures presented here can predict PFS, we envision 7 
discovery of predictive biomarkers for the response to immunotherapies in the future. 8 
The role of the adaptive immune response in controlling growth and recurrence of human 9 
cancers has been controversial29. It is now generally accepted that a number of solid tumors 10 
are capable of inactivating an anti-tumorigenic immune response. Once tumor immune 11 
surveillance is overcome, the composition of the immune infiltrate changes and a pro-12 
tumorigenic leukocyte profile emerges. T-cells can be both tumor suppressing and tumor 13 
promoting depending on their downstream target-cells27. We characterized the tumor-14 
infiltrating leukocytes and found that once human PDAC becomes clinically detectable and 15 
thus resected, the adaptive immune response mediated by CD3+ and CD4+ cells effects 16 
tumor recurrence. Intratumoral T-cells could modify tumor-stroma or tumor-cells in ways that 17 
attenuate the metastatic potential of PDAC29,31. We found a positive correlation between the 18 
presence of markers for TH1 polarized memory T-cells (CD3+ and CD4+) and prolonged PFS. 19 
We argue that the trafficking properties and long-lasting anti-tumor capacity of memory T-20 
cells play a central role in the control of tumor recurrence.  21 
The ultimate goal of cancer immunotherapy is to induce high affinity cytotoxic T-cells without 22 
causing autoimmunity32. The accumulation of cytotoxic CD8+ T-cells correlates well with 23 
survival of patients with different types of cancer as well as PDAC33–35,25,36. We confirmed 24 
these findings in our cohorts.  25 
Tumor-associated macrophages (CD68+ cells) are the most prevalent population of the 26 
tumor-infiltrating mononuclear cells. In addition, TAMs have also been suggested to promote 27 
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immune tolerance, at least in part by modulating the phenotype of tumor-infiltrating CD8+ T-1 
cells with CD8+ cell populations in the microenvironment being dependent on TAMs37. We 2 
show a significant and positive correlation between infiltration of CD68+ TAMs and increased 3 
PFS supporting previous mechanistic studies38. Moreover, TAMs proved to be independent 4 
predictive markers for recurrence after resection of PDAC. In addition, we detected 5 
significant differences in high CD206 expression in predicting increased PFS.  6 
Plasticity is a hallmark of TAMs, as they can acquire both pro-tumorigenic and anti-7 
tumorigenic phenotypes. Alternatively, polarized ΦM2 are believed to be major contributors to 8 
the immunosuppressive environment of the tumor. Contrary to these findings, we observed 9 
that high infiltration of ΦM2 increased PFS in the identification cohort but could not validate 10 
this finding. Only tumors with high infiltration of ΦM2 can obtain a prognostic advantage in 11 
response to chemotherapy whereas this effect is lost in sparsely infiltrated tumors39,40.  12 
A fibro-inflammatory stromal reaction influences PDAC initiation, progression, and relapse41. 13 
Stroma is believed to enhance stiffness, elevate hydrostatic pressure and contribute to 14 
cancer hypoperfusion and hypoxia42,43. However, depletion of stroma in experimental models 15 
resulted in a biologically more active and aggressive PDAC phenotype5,8. The function of the 16 
desmoplastic stroma is likely dynamic during cancer progression and its heterogeneous 17 
cellular and acellular constituents change in relation to the prognostic landscapes of 18 
cancers8,41. The expression of α-smooth muscle actin (α-SMA) in PSCs marks the 19 
transdifferentiation of the quiescent PSCs to an activated phenotype. The putative role of 20 
activated PSCs is to secrete various cytokines, chemokines and growth factors and thereby 21 
contribute to the inflammatory milieu stimulating cancer cell proliferation and migration. There 22 
are several studies depicting differential expression of α-SMA and collagen I, as a tumor-23 
promoter or -suppressor depending on stromal turn-over serving as an independent 24 
prognostic marker5,8,10. Our data support the previous finding that poor-prognosis stroma 25 
subtypes are characterized by the differential expression of α-SMA and collagen-I19 which led 26 
us to speculate that distinct stromal subtypes might be responsible for aggressiveness and 27 
associated with differential infiltration of immune cells. Having classified stromal composition 28 
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based on α-SMA and collagen I expression as inert, dormant, fibrogenic and fibrolytic 1 
stroma, we applied these subtypes to our cohort. We detected fibrolytic stroma indicating 2 
worse prognosis, thus confirming the previously published data10.  3 
The presence of tumor infiltrating leukocytes (TILs) within the tumor microenvironment is 4 
considered to be an indication of the host immune response to the tumor and reflects the 5 
dynamic process of cancer immunoediting23. There is evidence suggesting an interplay 6 
between cancer associated fibroblasts and immune cells in cancer development with a 7 
striking imbalance between pro-tumorigenic and anti-tumorigenic leukocyte 8 
subpopulations32,44. In the present study, we present a complex pattern of differential 9 
expression profiling of leukocyte subpopulations with an orthogonal behavior with respect to 10 
stromal subtypes for most TIL subtypes; being positively correlated with each other 11 
irrespective of stromal composition.  12 
Some tumors acquire the ability to sabotage the inflammatory response and exploit them to 13 
promote tumorigenesis. For this reason, the leukocyte infiltrate in the microenvironment and 14 
stromal composition may be a consequence of an inflammatory response that favors either 15 
dissemination of tumor cells or is immunosuppressive33. The independent prognostic 16 
potential of individual markers such as CD3, CD8, CD68 and CD206 which are confounders 17 
of stromal composition is thus limited. Therefore, we developed prognostic signatures to 18 
predict recurrence incorporating these confounding markers.  19 
In patients undergoing surgical resection of PDAC, prognosis and management are currently 20 
entirely based on tumor grading, nodal status and post-operative serum CA19-9 levels21,45 21 
despite considerable variability in outcome. Accordingly, prognostic classifiers that readily 22 
implement heterogeneity and type of tumor composition are needed to foster decision 23 
making and patients’ stratification. Here, implementing recursive-partitioning of discrete-PFS-24 
trees, we classified patients into 7 subtypes based on expression of CD3, CD4, CD8, CD68, 25 
CD206 and stromal composition. On the basis of this classification, we found statistically 26 
significant associations of these signatures in predicting recurrence. Of note, since all the 27 
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prognostic markers incorporated in the signatures had independent prognostic potential, no 1 
interaction was found between different signatures. Patients harboring CD3highCD206high 2 
signature have the best post-operative PFS whereas patients with CD3lowCD8lowCD68high 3 
signature showed the worst PFS. Moreover, these signatures minimize false negative cases 4 
obtained by employing single prognostic markers. Our findings support previous mechanistic 5 
data and demonstrate the ability of prognostic signatures to predict clinical outcome. The 6 
independent validation confirmed the performance of a prognostic histological signature and 7 
showed strong reproducibility and robustness of the signature. 8 
Despite several important observations, our study has limitations which include the 9 
retrospective design and inability to examine the predictive potential of our prognostic 10 
signature in correlation with treatment responses. While an effort was made to control for 11 
multiple comparisons for marker stratifications in low and high expression group, pairwise 12 
comparisons with p-values that are close to the 0.05 significance level should be interpreted 13 
with caution. We acknowledge that other molecular events within the prognostic signature 14 
could have an additional profound impact on prognosis and adjuvant chemotherapy does 15 
have an impact on recurrence rates.  16 
In conclusion, we defined a prognostic signature incorporating prognostic landscapes of 17 
tumor infiltrating leukocytes and stromal composition that can identify distinct subtypes with 18 
respect to recurrence within a cohort of resected PDAC patients and independently validated 19 
these signature. These data represent the largest and most comprehensive analysis to date 20 
for prognostic signatures for tumor infiltrating leukocytes and stromal composition and their 21 
prognostic effects. When thinking about adjuvant immunomodulatory therapy such as using 22 
M2-macrophage inhibitors or JAK inhibitors such signatures could become the basis for 23 
stratification.   24 
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Figure legends:  1 
Figure 1: Low expression levels of tumor infiltrate leukocytes correlate with poor 2 
progression free survival across resected PDAC. (A) CONSORT diagram. 5FU/FA = 5-3 
fluorouracil/folinic acid; FFPE = formalin-fixed paraffin-embedded; PDAC = pancreatic ductal 4 
adenocarcinoma; TMA = tissue microarray. (B) Representative image showing analysis of 5 
immune infiltration (number of cells/mm2) using an algorithm developed for NIH ImageJ 6 
software. (C) The Kaplan-Meier survival analysis shows that patients with low CD3 7 
expression are burdened with as decreased progression free survival time in comparison to 8 
high CD3 expression.  9 
Figure 2: Contribution of multifaceted stromal composition in defining progression 10 
free survival. (A) Representative images of α-SMA and collagen-I staining characterizing 11 
fibrogenic, inert, dormant and fibrolytic stroma. (B) Kaplan-Meier survival analysis of patients 12 
with resected PDAC in respect to stroma subtype with median survival for inert stroma (light 13 
green) as 13.76 (95%CI 10.94-16.65), dormant stroma (orange) as 12.81 (95% CI 9.88-14 
16.06), fibrogenic stroma (light blue) as 14.09 (95% CI 11.99-20.10) and fibrolytic stroma 15 
(red) as 11.03 (95%CI 8.87-12.74). (C) Correlation matrixes demonstrating results of the 16 
correlation analyses followed by unsupervised hierarchical clustering between leukocyte 17 
subpopulations and corresponding stromal composition. (D) Box and whisker plot comparing 18 
the differential distribution of leukocyte subpopulations in different stromal composition with 19 
p-values from Kruskal-Wallis testing with Dunn post-hoc.  20 
Figure 3: Inferred leukocyte subtype frequencies associated with prognostic 21 
association in determining progression free survival corresponding to stromal 22 
composition. (A) Random forest iterations determine “variable of importance (VIMP)” and 23 
minimal depth of the prognostic variables in determining progression free survival. Longer 24 
VIMP bars with shorter minimal depth bars indicate a higher effect of the variable. Area 25 
shaded in grey depicts the prognostic window for the prognostic variables. (B) Multivariate 26 
recursive partitioning for discrete-time survival tree for progression free survival depicting 27 
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prognostic signatures amalgating two or more markers with median progression free survival 1 
varying between 7.95 months to 16.60 months with a relative error of prediction given with 2 
0.08 (X-error -0.02). (C) Waterfall plot of each prognostic signature as delineated from the 3 
terminal nodes illustrating the relative prognostic index of each signature calculated using 4 
Cox multivariate proportional hazards. (D) Alluvial plot depicting prediction accuracy of 5 
response (predicted m(pfst) per subcohort) in comparison with actual response (actual 6 
m(pfst) per subcohort) in the validation cohort. Left side of the alluvial plot depicts predicted 7 
response per node and right depict actual response per node of the validation cohort. Blue 8 
area connecting left to the right graph represent perfect match while red area represent 9 
mismatch in the response. The thickness of the color areas depicts the number of subjects. 10 
P<0.05 is considered as significant.  11 
 12 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1 
 
Table 1: Demographic, surgery and pathology features of the patients scored for 
multifaceted stromal composition. 
Demographics  Total  
Characteristics    
  N=385 
Age Median (IQR) years 64 (32-83) 
Sex  Female  160 
  Male  225 
WHO Performance score 0 128 
1 210 
2 47 
Diabetes N=368 
  No  291 
  IDDM  46 
  NIDDM  31 
Smoking N=345 
  Never  149 
  Past  135 
  Present  61 
Post-Op. CA 19-9 Median (IQR) KU/l  N=290 
27 (0-27016) 
Surgery to Randomisation Median (IQR) days  49 (4-92) 
Surgery N=373 
  Whipples resection 193 
  Pylorus preserving 147 
  Distal pancreatectomy 20 
  Total pancreatectomy 13 
Extent of resection N=366 
  Standard 274  
  Radical 53  
  Extended Radical 39  
Maximum tumor diameter. mm median (IQR) N=377 
30 (3-350) 
Differentiation status N=378 
  Well 30  
  Moderate 246 
  Poor 102  
Lymph Node Invasion Negative 84  
  Positive 301 
Resection Margin Negative 215  
  Positive 170 
Local Invasion N=372 
  No  199 
  Yes  173  
Tumor Stage N=380 
  I 26 
  II 100 
  III 243 
  IV 11 
CD3 N=385 
  Low 186  
High 199  
CD4 N=342 
  Low 56  
High 286 
CD8 N=365 
  Low 151  
High 214  
CD68 N=383 
  Low 175  
High 208  
CD206 N=350 
  Low 81  
High 269 
Neutrophils  N=359 
  Low 180  
High 179  
Stroma  N=384 
Tables 1-4
2 
 
Demographics  Total  
Characteristics    
 Fibrolytic 102 
 Inert 96 
 Dormant 96 
 Fibrogenic 90 
Therapeutic Arm  N=385 
 5FU 190 
 Gemcitabine 195 
 3 
 
Table 2: Tabular representation of the Kaplan-Meier survival analysis depicting influence of high and low expression of immune infiltrate markers, CD3, 
CD4, CD8, CD68, CD206 and neutrophils in predicting PFS and OS. 
Immune markers stratification 
Progression free survival Overall survival 
m(pfst) 2 p m(st) 2 p 
CD3 
Low 11.03 (95%CI: 9.69-12.45) 
15.20 <0.001 
20.13 (95%CI: 16.39-22.60) 
9.60 0.001 
High 14.32 (95%CI: 12.74-17.28) 25.95 (95%CI: 22.53-29.17) 
CD4 
Low 10.87 (95%CI: 9.23-14.19) 
4.50 0.03 
21.94 (95%CI: 14.98-27.40) 
2.30 0.12 
High 12.81 (95%CI: 11.72-14.91) 24.34 (95%CI: 20.89-26.44) 
CD8 
Low 12.05 (95%CI: 10.11-13.83) 
4.30 0.03 
21.22 (95%CI: 16.26-27.49) 
3.30 0.07 
High 13.10 (95%CI: 11.72-15.93) 24.34 (95%CI: 20.63-27.49) 
CD68 
Low 11.72 (95%CI: 9.36-13.60) 
5.00 0.02 
20.40 (95%CI: 16.62-24.11) 
4.50 0.03 
High 13.30 (95%CI: 111.92-16.39) 25.52 (95%CI: 21.78-28.78) 
CD206 
Low 10.28 (95%CI: 8.60-12.74) 
7.40 0.006 
16.91 (95%CI: 13.89-22.24) 
11.50 <0.001 
High 13.76 (95%CI: 11.99-15.63) 25.95 (95%CI: 22.43-28.78) 
Neutophils 
Low 13.60 (95%CI: 11.99-15.34) 
0.01 0.87 
25.13 (95%CI: 21.22-28.02) 
0.50 0.49 
High 11.95 (95%CI: 10.54-15.04) 22.04 (95%CI: 16.82-25.69) 
 
 
 4 
 
Table 3: Influence of immune infiltration with respect to stromal composition 
Immune markers Stroma type Stratification 
Progression free survival 
m(pfst) - 95%CI 𝜒2 p 
CD3 
Fibrogenic 
Low 11.26 (6.63-17.80) 
6.50 0.01 
High 20.10 (12.81-24.73) 
Inert 
Low 12.45 (9.98-15.93) 
3.30 0.07 
High 16.65 (9.79-26.67) 
Dormant 
Low 10.64 (8.77-16.06) 
2.60 1.1 
High 14.32 (12.74-17.28) 
Fibrolytic 
Low 9.52 (7.58-12.05) 
4.10 0.04 
High 12.38 (8.87-14.32) 
CD4 
Fibrogenic 
Low 10.71 (6.30-14.09) 
7.50 0.006 
High 19.08 (12.81-24.73) 
Inert 
Low 17.64 (7.88-38.80) 
0.20 0.63 
High 12.5 (10.11-16.65) 
Dormant 
Low 9.88 (6.17-20.30) 
3.50 0.06 
High 14.34 (9.95-19.12) 
Fibrolytic 
Low 11.03 (8.34-13.83) 
0.01 0.87 
High 10.84 (8.87-14.32) 
CD8 
Fibrogenic 
Low 17.80 (6.63-23.35) 
0.10 0.76 
High 13.33 (11.72-20.36) 
Inert 
Low 11.63 (8.44-16.65) 
2.00 0.15 
High 16.32 (11.13-29.14) 
Dormant 
Low 11.30 (7.81-15.04) 
1.00 0.31 
High 13.14 (9.95-20.30) 
Fibrolytic 
Low 11.00 (8.27-13.83) 
0.80 0.37 
High 11.05 (8.41-15.34) 
CD68 
Fibrogenic 
Low 18.79 (7.12-21.97) 
0.10 0.74 
High 14.09 (11.79-21.61) 
Inert 
Low 11.07 (9.19-15.40) 
4.60 0.03 
High 17.64 (11.63-26.25) 
Dormant 
Low 10.94 (7.91-15.63) 
0.40 0.50 
High 13.76 (9.88-20.23) 
Fibrolytic 
Low 11.03 (8.27-14.19) 
0.30 0.57 
High 10.56 (7.95-12.74) 
CD206 
Fibrogenic 
Low 11.00 (7.98-17.80) 
3.60 0.05 
High 19.71 (12.81-24.73) 
Inert 
Low 15.93 (4.30-22.93) 
0.10 0.74 
High 13.02 (10.11-16.65) 
Dormant 
Low 9.59 (6.01-12.41) 
11.60 0.0006 
High 15.63 (10.64-22.89) 
Fibrolytic 
Low 8.96 (4.66-15.63) 
0.10 0.80 
High 11.17 (8.73-13.83) 
Neutrophils 
Fibrogenic 
Low 19.28 (12.45-23.35) 
0.60 0.45 
High 12.81 (9.49-21.61) 
Inert 
Low 14.76 (10.51-20.40) 
0.99 0.884 
High 13.09 (9.16-20.36) 
Dormant 
Low 11.92 (8.60-15.63) 
0.99 0.31 
High 13.04 (9.69-22.89) 
Fibrolytic 
Low 11.61 (8.27-14.25) 
0.99 0.84 
High 10.18 (7.95-15.34) 
  
 5 
 
Table 4: Univariate analysis of progression free survival factors. 
Characteristic Univariate analysis Multivariate analysis 
Age 0.99 (0.98 to 1.01) 
2=1.29 (P=0.25) 
 
Sex  Female  1(Referent)  
Male  0.88 (0.71 to 1.09) 
2=1.36 (P=0.24) 
 
Smoking  Never  1(Referent)  
Past  1.08 (0.84 to 1.38) 
2=2.67 (P=0.51) 
 
Present  1.29 (0.94 to 1.77) 
2=2.00 (P=0.10) 
 
Lymph Node 
Invasion  
Negative 1(Referent)  
Positive 1.95 (1.47 to 2.58) 
2=21.84 (P<0.0001) 
 
 
Resection 
Margin  
Negative 1(Referent)  
Positive 1.59 (1.28 to 1.97) 
2=18.21 (P<0.0001) 
 
Local 
Invasion  
No  1(Referent)  
Yes  1.30 (1.05 to 1.61) 
2=5.91 (P=0.01) 
 
Tumor 
Stage  
I 1(Referent)  
II 1.56 (0.92 to 2.62) 
2=13.10 (P=0.09) 
 
III 2.08 (1.27 to 3.42) 
2=3.00 (P=0.003) 
 
IV 1.31 (0.58 to 2.94) 
2=0.004 (P=0.51) 
 
 
Post-operative CA19.9 1.00 (1.00 to 1.01) 
2=13.49 (P=0.0002) 
 
 
Maximum tumor size 1.00 (0.99 to 1.00) 
2=2.09 (P=0.14) 
 
 
Differentiation 
status  
well 1(Referent)  
moderate 0.91 (0.61 to 1.34) 
2=1.85 (P=0.63) 
 
 
poor 1.07 (0.70 to 1.63) 
2=2.00 (P=0.73) 
 
WHO 
Performance 
score 
0 1(Referent)  
1 1.12 (0.88 to 1.42) 
2=1.02 (P=0.31) 
 
 
2 1.06 (0.75 to 1.53) 
2=2.00 (P=0.69) 
 
CD3 Low 1(Referent) 1(Referent) 
High 0.65 (0.52 to 0.80) 
2=14.96 (P=0.0001) 
0.69 (0.54 to 0.89) 
z-stat=-2.79 (P=0.005) 
CD4 Low 1(Referent) 1(Referent) 
High 0.72 (0.54 to 0.97) 
2=4.49 (P=0.03) 
0.78 (0.56 to 1.08) 
z-stat=-1.46 (P=0.14) 
CD8 Low 1(Referent) 1(Referent) 
High 0.78 (0.63 to 0.98) 
2=4.25 (P=0.03) 
0.72 (0.55 to 0.95) 
z-stat=-2.27 (P=0.02) 
CD68 Low 1(Referent) 1(Referent) 
High 0.78 (0.62 to 0.97) 
2=4.93 (P=0.02) 
0.83 (0.64 to 1.08) 
z-stat=-1.37 (P=0.16) 
CD206 Low 1(Referent) 1(Referent) 
High 0.69 (0.52 to 0.90) 
2=7.36 (P=0.006) 
0.64 (0.47 to 0.87) 
z-stat=-2.87 (P=0.004) 
Neutrophils Low 1(Referent)  
High 0.98 (0.78 to 1.22) 
2=0.03 (P=0.87) 
 
Stroma Fibrolytic 1(Referent) 1(Referent) 
 Inert 0.76 (0.56 to 1.03) 
2=7.10 (P=0.08) 
0.75 (0.55 to 1.06) 
z-stat=-1.63 (P=0.10) 
 Dormant 0.77 (0.57 to 1.04) 
2=3.00 (P=0.09) 
0.85 (0.61 to 1.19) 
z-stat=-0.92 (P=0.35) 
 Fibrogenic 0.66 (0.48 to 0.90) 
2=0.06 (P=0.01) 
0.73 (0.52 to 1.02) 
z-stat=-1.80 (P=0.07) 
Concordance  0.61 ± 0.01 
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WHAT YOU NEED TO KNOW 
Background and context 
Pancreatic ductal adenocarcinoma (PDAC) is accompanied by a high desmoplastic reaction and 
an immunosuppressive microenvironment. Differential stromal composition categorized by 
activated myofibroblasts and collagen expression is an independent prognostic marker in 
predicting outcome of PDAC patients. Though immunosuppressive PDAC presents with the 
inherent capacity to activate T-cell-mediated anti-tumour response, the exact nature of the 
complex interaction between desmoplastic stroma and leukocytes infiltration and its impact on 
PDAC patient prognosis remains unknown. 
New Findings 
This study demonstrates the clinical impact of leukocyte subpopulations and differential stromal 
compositions forming PDAC microenvironment. It provides a robust and independently validated 
leukocyte and stromal composition-based prognostic signature that correlates to progression 
free survival in patients with PDAC. 
Limitations 
This study has limitation including the retrospective design and the inability to study the 
predictive potential of the prognostic histological signature in correlation with a treatment 
response. 
Impact 
Tissue-typing the microenvironment of PDAC and using it as a prognostic signature may aid in 
stratifying the patients for immunomodulatory therapy as a step towards precision medicine.  
 
 
"What You Need to Know"
 1 
LAY SUMMARY 
The prognosis of pancreatic cancer is poor. To understand the influence of tissue composition 
(tumor cells, immune cells, stroma cells) of pancreatic cancer we developed a histological 
signature associated with a poorer outcome. Furthermore, we propose that the immune infiltrate 
determines tissue composition and not stromal cells.  
"Lay Summary"
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Immune Cell and Stromal Signature Associated with Progression-free Survival of 1 
Patients with Resected Pancreatic Ductal Adenocarcinoma  2 
U. M. Mahajan1,2, E. Langhoff2, E. Goni1, E. Costello3, W. Greenhalf3, C. Halloran3, S. 3 
Ormanns4, S. Kruger5, S. Böck5, S. Ribback6, G. Beyer1,2, F. Dombroswki6, F.-U. Weiss2, J. 4 
P. Neoptolemos3,7, J. Werner8, J. G. D’Haese8, A. Bazhin8, J. Peterhansl1, S. Pichlmeier1, M. 5 
W. Büchler7, J. Kleeff9, P. Ganeh3, M. Sendler2, D. H. Palmer3,10, T. Kohlmann11, R. Rad12, I. 6 
Regel1, M.M. Lerch2, J. Mayerle1,2 7 
Supplementary materials and methods 8 
Manufacturing of tissue microarrays (TMAs) 9 
All TMAs were manufactured using standard operating procedures conducted to Good 10 
Laboratory Practice. Cores were taken from tumor regions identified by an experienced 11 
pancreatic pathologist using hematoxylin-eosin stained sections as reference. TMAs from the 12 
training cohort contained cores from patients of the chemotherapeutic arm of the ESPAC-1 13 
trial and from patients of the ESPAC-3 trial randomized to either 5FU/folinic acid or to 14 
gemcitabine. TMAs were prepared with two cores from each block, with four to eight cores 15 
arrayed for each patient. For all arrays control cores, comprising 3 cores each of colon, 16 
kidney, liver, normal pancreas and chronic pancreatitis, were arranged in a fence around the 17 
test samples as described previously1. Although fixation protocols for formalin-fixed paraffin 18 
embedded tissue blocks varied across centers, they were standardized for each center with 19 
no evidence for the centre- or country-specific bias in immunostaining. TMAs used for the 20 
validation cohort consist of randomly selected PDAC cases resected between 2011 and 21 
2017 at the Department of General, Visceral and Transplantation Surgery, University 22 
Hospital, LMU Munich, Germany. TMA construction was reported previously2.  23 
Single and multiplex immunostaining 24 
Immunostaining of the TMAs from the training cohort was performed on 2μm sections for α-25 
SMA (mouse anti-human α-SMA, Dako clone 1A4, 1:800), CD3 (mouse anti-human CD3, 26 
Dako clone F7.2.38, 1:100), CD4 (rabbit anti-human CD4, Cell Marque clone SP35, 1:100), 27 
CD8 (mouse anti-human CD8, Dako clone C8/144B, 1:100 ), CD68 (mouse anti-human 28 
Supplementary methods Click here to access/download;Supporting Document;9.
Mahajan et al 2018 supplementary methods v7.docx
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CD68, Dako clone PS-M1, 1:100) and CD206 (mouse anti-human CD206, R&D systems 1 
clone 685645, 1:40) as described earlier3. Briefly, after deparaffinization and rehydration of 2 
sections, antigens were retrieved by heat treatment in citrate buffer pH 6.0 (Dako 3 
Deutschland GmbH, Hamburg, Germany). After peroxidase block, slides were incubated with 4 
the primary antibodies at 4 °C overnight. Detection was performed after specific secondary 5 
antibody incubation using DAB complex conjugation reagent (vector Laboratories Ltd., 6 
Peterborough, UK). Negative controls were incubated with buffer alone, in place of primary 7 
antibody. 8 
Chloracetate esterase staining for detection of neutrophils infiltration was performed using 9 
Naphthol AS-D chloroacetate (specific esterase) kit (Sigma-Aldrich) according 10 
manufacturer’s instruction. Collagen staining was performed using Picrosirius red - Fast 11 
green staining solution (0.1% direct Red 80 and 0.1% Fast green FCF in aqueous picric 12 
acid). Briefly, after deparaffinization, tissue microarrays sections were incubated in 13 
Picrosirius red - Fast green staining solution for 60 minutes at room temperature, followed by 14 
dehydration and fixation.  15 
For the validation cohort, multiplex immunostaining on TMAs was performed as described 16 
previously with some modifications4. The flow of multiplex immunostaining is delignated in 17 
suppl fig. 11, using one slide for multiple staining. Briefly, after deparaffinization, slides 18 
where stained with haematoxylin followed by 2 min incubation in 0.5 % ammonia solution. 19 
Slides were mounted using aqueous mounting media. Whole slides were scanned in Sysmex 20 
Panoramic MIDI II slide scanner (Sysmex Deutschland GmbH, Bornbarch, Germany). After 21 
scanning, coverslips were removed by immersing slide in PBS for 5 min. Slides were then 22 
subjected to antigen retrieval (Dako Antigen retrieval buffer, Dako Deutschland GmbH, 23 
Hamburg, Germany), blocking with 1% Aurion BSA-cTM (Aurion, Wageningen, The 24 
Netherlands) in PBS and first primary antibody incubation as described previously5. Next 25 
day, following secondary antibody incubation and washing, staining was performed using 26 
ImmPACT AMEC red (Vector Labs, Burlingame, USA) substrate. Slides were then mounted 27 
using aqueous mounting media and scanned in Sysmex Panoramic MIDI II slide scanner. 28 
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After removing coverslips, AMEC red destaining of the slides was performed as described6 1 
by dipping slides in 70 % ethanol for 2 min, followed by 95 % ethanol and 70 % ethanol and 2 
PBS for 2 min each. Next, antibody stripping was performed as described7. Here, slides were 3 
incubated with preheated solution of 25 mM Glycine, 1 % SDS, pH 2.0 for 30 min at 50 °C. 4 
After cooling, slides were proceeded for next primary antibody incubation. The flow was 5 
repeated for multiple antibodies used in following consecutive order: CD3, CD4, CD8, CD45, 6 
CD68, CD206, MPO and α-SMA (applied with the same dilutions as noted above). Lastly, the 7 
TMA slides were stained for Picrosirius red - Fast green as described above. 8 
Image cytometry 9 
All multiplex slides scans were processed as shown in suppl fig.11. Each core for each 10 
single staining (immune cell marker, α-SMA, collagen and hematoxylin; in total 10) was 11 
selected and matched for slide co-ordinates. All images were saved as TIFF files. Next, all 12 
the images were adjusted towards an intensity threshold and compensated using an in-13 
house algorithm for NIH ImageJ software. For each staining, the images were sorted 14 
according their core ID and each of the 10 images per core were aligned pixel to pixel using 15 
in-house algorithm developed for NIH ImageJ software. Following alignment, images were 16 
subjected to colocalization analysis using algorithm developed for Cell Profiler software and 17 
described by Tsujikawa et al4 with some modifications. The output files were then processed 18 
using FCS express 6 (DeNovo software, San Jose, USA) for image cytometric analysis 19 
similar to FACS analysis with appropriate gating. For all the markers, separate pseudo-color 20 
was assigned and colocalization  were observed by merging all images per IDs. NIH ImageJ 21 
software algorithms can be provided upon request. 22 
Primary cell isolation from tumor tissue 23 
Isolation of intra-tumoral cells (ITCs) from freshly resected PDAC tumors (n=10) were 24 
performed as described previously8. Briefly, following resection, tumor samples were 25 
transferred in PBS including 1% Soybean trypsin inhibitor (ThermoFischer Scientific, 26 
Waltham, USA). Tumor samples were afterwards digested in 2 mg/ml Collagenase IV 27 
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(Serva, Heidelburg, Germany), 1 mg/ml hyaluronidase (Serva, Heidelburg, Germany), 1 % 1 
Soybean trypsin inhibitor and 0.1 mg/ml DNase I (ThermoFischer Scientific) solution. For an 2 
appropriate digestion, tumor tissue was minced into small pieces and incubated for 45 min at 3 
37°C at 60 rpm in a water bath. Following incubation, suspension was filter through a 100µm 4 
nylon mesh and centrifuged for 10 min at 400g at 4oC. The obtained cell pellet was 5 
resuspended in PBS and 1x106 cells were cryopreserved in 1 ml of freezing media (10% 6 
DMSO, 90 % FCS) at -150°C for flow cytometry analysis. 5x106 cells were used for cytospins 7 
and cytoblock preparation, respectively. 8 
Cytoblock and Cytospin slide preparation 9 
After ITC isolation, cells were fixed in 4% buffered-PFA and processed in the Department of 10 
Pathology, University Hospital, LMU Munich, Germany for cytoblock preparation. Cytospins 11 
were prepared by pipetting 120µl (approx. 5x105 cells) of the cell suspension in a funnel 12 
using Cytospin 4 (Thermo Scientific, Waltham, USA) and centrifuged at 800 rpm for 10 min 13 
and stained as described in Material and Methods section. 14 
Peripheral blood derived monocytes cell (PBMC) isolation 15 
PBMCs from 5 ml of intraoperative blood were isolated as described previously9 using Ficoll 16 
gradient. 1x106 cells were cryopreserved in 1 ml of freezing media (10% DMSO, 90% FCS) 17 
at -150°C for flow cytometry analysis. 18 
Flow cytometry 19 
Flow cytometry analysis of ITCs and PBMCs was performed as described previously8,10. 20 
Isolated ITCs and PBMCs were resuspended and washed with FACS buffer (PBS, 0.5% 21 
BSA, 2mM EDTA) at 700g for 5 min and subsequently incubated with 2 ml FcR receptor 22 
blocking solution (Human BD Fc BlockTM, BD Biosciences, Heidelberg, Germany) for 15 min 23 
at 4 °C. After dilution to 2.5x105 cells/ml and two more washing steps, leukocytes were 24 
labelled using the following fluorescence labelled anti-human antibodies: CD45 (BD 25 
Horizon™ BV650), CD3 (BD PerCP-Cy5.5), CD4 (BD Horizon™ BUV395), CD8 (BD APC-26 
Cy7), CD68 (BD BV421) and CD206 (BD Pharmingen™ PE, all from BD Biosciences, 27 
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Heidelberg, Germany). After adding 3 μl of antibody solution, tubes were incubated at 4 °C 1 
for 30 min in the dark. Unbound antibodies were washed away at 700g for 5 min and cells 2 
were stored in 300μl FACS buffer at 4°C until analysis. Cells were analyzed using BD 3 
LSRFortessa (BD Biosciences, Heidelberg, Germany) and FCS express 6 (DeNovo 4 
software, San Jose, USA). 5 
Addition notes 6 
All the analysis R scripts will be provided on request. 7 
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Supplementary Table S1: Cut-off for low/high expression determined by cut-off finder 
Sr. No Marker Low expression High expression 
1 -SMA* ≤ 10.41 > 10.41 
2 Collagen§ ≤ 0.93 > 0.93 
3 CD3† ≤ 63.25 > 63.25 
4 CD4† ≤ 5.5 > 5.5 
5 CD8† ≤ 60.75 > 60.75 
6 CD68† ≤ 8.34 > 8.34 
7 CD206† ≤ 30.25 > 30.25 
8 CAE (Neutrophils) † ≤ 18.25 > 18.25 
* H-score for intensity score and % stained area 
§ H-score calculated based on intensity score and ratio of % stained area of Picrosirius red 
(Collagen) and Fast Green (all tissues) 
† Median count of immune infiltrate per unit mm3. 
Supplementary table 1 Click here to access/download;Supporting Document;10.
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Supplementary Table 2: Relationship between Immune markers and patient or tumour characteristics.
Low CD3 High CD3 Total P Value Low CD4
0 53 75 128 (33.2%) 12
1 104 106 210 (54.5%) 33
2 29 18 47 (12.2%) 11
<30mm 91 129 220 (60.8%) 31
≥30mm 84 58 142 (39.2%) 20
Female 83 77 160 (41.6%) 28
Male 103 122 225 (58.4%) 28
5FU 83 107 190 (49.4%) 48
GEM 103 92 195 (50.6%) 8
Well 15 15 30 (7.9%) 2
Moderate 114 132 246 (65.1%) 32
Poor 54 48 102 (27.0%) 19
1 13 13 26 (6.8%) 5
2 45 55 100 (26.3%) 13
3 118 125 243 (63.9%) 36
4 7 4 11 (2.9%) 1
Negative 38 46 84 (21.8%) 9
Positive 148 153 301 (78.2%) 47
Negative 100 115 215 (55.8%) 29
Positive 86 84 170 (44.2%) 27
No 142 149 291 (79.1%) 44
IDDM 24 22 46 (12.5%) 9
NIDDM 14 17 31 (8.4%) 2
Never 74 75 149 (43.2%) 26
Past 62 73 135 (39.1%) 21
Present 34 27 61 (17.7%) 7
NO 93 106 199 (53.5%) 27
YES 89 84 173 (46.5%) 29
<64 91 106 197 (51.2%) 30
≥64 95 93 188 (48.8%) 26
<27 69 71 140 (50.4%) 28
≥27 72 66 138 (49.6%) 20
<49 94 103 197 (51.2%) 28
≥49 92 96 188 (48.8%) 28
Low 43
High 13
Low 43 13 56 (16.3%)
High 118 169 287 (83.7%)
Low 71 77 148 (41.1%) 10
High 98 114 212 (58.9%) 46
Low 97 77 174 (45.5%) 11
High 87 121 208 (54.5%) 45
Low 38 43 81 (23.3%) 27
High 124 143 267 (76.7%) 28
Low 87 90 177 (50.0%) 26
High 82 95 177 (50.0%) 30
Fibrolytic 43 57 100 (26.3%) 9
Inert 52 43 95 (24.9%) 7
Dormant 54 43 97 (25.4%) 25
Fibrogenic 35 55 90 (23.6%) 15
Diabetes
Smoke
Lymph Node Status
Resection Margin
0.606
0.718
0.891
CD3
CD4
CD8
Neutrophils
CD68
CD206
Local Invasion
Age(Years)
CD4
Maxium Tumour Diameter
Tumour Stage
Gender
Chemotherapy 
Tumour Grade
WHO Performance Scale
Characteristics
0.051
CD3
0.001
0.282
0.091
0.525
0.681
0.489
0.830
0.442
0.422
0.454
Stroma 0.046
Post Op CA19-9 (Units)
Surgery to Randomisation 
(Days)
0.670
<0.0001
0.826
0.009
0.958
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High CD4 Total P Value Low CD8 High CD8 Total P Value Low CD68
106 118 (34.5%) 53 73 126 (34.5%) 57
154 187 (54.7%) 84 114 198 (54.2%) 98
26 37 (10.8%) 14 27 41 (11.2%) 20
164 195 (60.7%) 79 130 209 (60.8%) 96
106 126 (39.3%) 62 73 135 (39.2%) 69
116 144 (42.1%) 59 93 152 (41.6%) 72
170 198 (57.9%) 92 121 213 (58.4%) 103
119 167 (48.8%) 26 157 183 (50.1%) 49
167 175 (51.2%) 125 57 182 (49.9%) 126
22 24 (7.2%) 9 16 25 (7.0%) 18
192 224 (66.9%) 100 134 234 (65.4%) 110
68 87 (26.0%) 38 61 99 (27.7%) 44
16 21 (6.2%) 8 16 24 (6.6%) 9
73 86 (25.4%) 30 57 87 (24.1%) 41
185 221 (65.4%) 108 132 240 (66.5%) 115
9 10 (3.0%) 3 7 10 (2.8%) 6
62 71 (20.8%) 27 48 75 (20.5%) 32
224 271 (79.2%) 124 166 290 (79.5%) 143
161 190 (55.6%) 88 115 203 (55.6%) 99
125 152 (44.4%) 63 99 162 (44.4%) 76
216 260 (78.5%) 113 165 278 (79.0%) 130
36 45 (13.6%) 22 24 46 (13.1%) 23
24 26 (7.9%) 13 15 28 (8.0%) 13
107 133 (42.8%) 63 80 143 (43.2%) 64
103 124 (39.9%) 58 72 130 (39.3%) 64
47 54 (17.4%) 17 41 58 (17.5%) 26
154 181 (53.9%) 73 122 195 (54.6%) 94
126 155 (46.1%) 75 87 162 (45.4%) 76
152 182 (53.2%) 85 104 189 (51.8%) 92
134 160 (46.8%) 66 110 176 (48.2%) 83
97 125 (50.0%) 61 71 132 (49.8%) 61
105 125 (50.0%) 48 85 133 (50.2%) 63
146 174 (50.9%) 76 112 188 (51.5%) 88
140 168 (49.1%) 75 102 177 (48.5%) 87
118 161 (46.9%) 71 98 169 (46.9%) 97
169 182 (53.1%) 77 114 191 (53.1%) 77
10 46 56 (16.5%) 11
131 153 284 (83.5%) 150
131 141 (41.5%) 86
153 199 (58.5%) 78
150 161 (46.9%) 86 78 164 (45.8%)
137 182 (53.1%) 61 133 194 (54.2%)
54 81 (23.8%) 12 68 80 (23.2%) 30
232 260 (76.2%) 131 134 265 (76.8%) 133
141 167 (49.1%) 86 84 170 (49.3%) 87
143 173 (50.9%) 55 120 175 (50.7%) 78
83 92 (26.5%) 46 50 96 (26.8%) 53
72 79 (23.1%) 51 35 86 (24.0%) 58
61 86 (25.1%) 26 64 90 (25.1%) 29
70 85 (24.8%) 23 63 86 (24.0%) 34
CD68CD8
0.607
0.166
0.466
<0.0001
0.826
0.000
0.000
<0.0001
0.108
0.113
0.180
0.121
0.786
0.661
0.243
0.354
0.252
0.584
CD4
0.015
<0.0001
0.152
0.880
0.741
0.246
0.444
0.930
0.001
0.000
<0.0001
<0.0001
0.769
0.636
0.390
0.552
0.434
0.261
0.998
<0.0001
<0.0001
0.000
High CD68 Total P Value Low CD206 High CD206 Total P Value
Low 
neutrophils
71 128 (33.4%) 28 94 122 (34.9%) 56
111 209 (54.6%) 46 144 190 (54.3%) 101
26 46 (12.0%) 7 31 38 (10.9%) 23
123 219 (60.7%) 48 153 201 (61.1%) 105
73 142 (39.3%) 30 98 128 (38.9%) 66
88 160 (41.8%) 38 108 146 (41.7%) 74
120 223 (58.2%) 43 161 204 (58.3%) 106
138 187 (48.8%) 80 88 168 (48.0%) 66
70 196 (51.2%) 1 181 182 (52.0%) 114
11 29 (7.7%) 5 20 25 (7.3%) 17
136 246 (65.4%) 50 175 225 (65.6%) 117
57 101 (26.9%) 23 70 93 (27.1%) 42
16 25 (6.6%) 5 17 22 (6.4%) 9
59 100 (26.5%) 15 71 86 (24.9%) 39
127 242 (64.0%) 57 170 227 (65.6%) 126
5 11 (2.9%) 3 8 11 (3.2%) 3
51 83 (21.7%) 14 59 73 (20.9%) 34
157 300 (78.3%) 67 210 277 (79.1%) 146
114 213 (55.6%) 39 155 194 (55.4%) 105
94 170 (44.4%) 42 114 156 (44.6%) 75
161 291 (79.3%) 68 196 264 (78.6%) 140
23 46 (12.5%) 8 37 45 (13.4%) 24
17 30 (8.2%) 2 25 27 (8.0%) 10
84 148 (42.9%) 37 97 134 (42.4%) 68
72 136 (39.4%) 23 103 126 (39.9%) 70
35 61 (17.7%) 16 40 56 (17.7%) 28
105 199 (53.6%) 48 137 185 (54.3%) 82
96 172 (46.4%) 33 123 156 (45.7%) 95
106 198 (51.7%) 43 142 185 (52.9%) 85
102 185 (48.3%) 38 127 165 (47.1%) 95
80 141 (50.7%) 30 95 125 (49.2%) 63
74 137 (49.3%) 35 94 129 (50.8%) 63
108 196 (51.2%) 43 136 179 (51.1%) 89
100 187 (48.8%) 38 133 171 (48.9%) 91
87 184 (48.2%) 38 124 162 (46.6%) 87
121 198 (51.8%) 43 143 186 (53.4%) 90
45 56 (16.3%) 27 28 55 (16.1%) 26
137 287 (83.7%) 54 232 286 (83.9%) 141
61 147 (41.1%) 12 131 143 (41.4%) 86
133 211 (58.9%) 68 134 202 (58.6%) 84
30 133 163 (46.8%) 87
51 134 185 (53.2%) 90
51 81 (23.3%) 21
134 267 (76.7%) 148
90 177 (50.0%) 21 148 169 (49.3%)
99 177 (50.0%) 59 115 174 (50.7%)
46 99 (26.0%) 21 71 92 (26.4%) 50
36 94 (24.7%) 13 68 81 (23.2%) 40
68 97 (25.5%) 20 70 90 (25.8%) 49
56 90 (23.6%) 27 58 85 (24.4%) 37
Neutrophils CD206
0.741
0.967
0.340
<0.0001
0.839
0.537
0.455
<0.0001
<0.0001
0.059
0.169
0.064
0.144
0.364
0.936
0.669
0.785
0.958
<0.0001
CD68
0.839
0.437
0.900
<0.0001
0.059
0.394
0.000
0.764
0.629
0.833
0.737
0.828
0.009
<0.0001
0.182
0.479
0.177
0.808
0.778
<0.0001 0.118
High 
Neutrophils
Total P Value
65 121 (33.7%)
94 195 (54.3%)
20 43 (12.0%)
103 208 (61.7%)
63 129 (38.3%)
75 149 (41.5%)
104 210 (58.5%)
109 175 (48.7%)
70 184 (51.3%)
11 28 (8.0%)
114 231 (65.6%)
51 93 (26.4%)
12 21 (5.9%)
48 87 (24.5%)
110 236 (66.5%)
8 11 (3.1%)
38 72 (20.1%)
141 287 (79.9%)
95 200 (55.7%)
84 159 (44.3%)
132 272 (78.6%)
21 45 (13.0%)
19 29 (8.4%)
71 139 (42.6%)
60 130 (39.9%)
29 57 (17.5%)
107 189 (53.8%)
67 162 (46.2%)
103 188 (52.4%)
76 171 (47.6%)
67 130 (49.8%)
68 131 (50.2%)
94 183 (51.0%)
85 176 (49.0%)
82 169 (47.7%)
95 185 (52.3%)
30 56 (16.5%)
143 284 (83.5%)
55 141 (40.9%)
120 204 (59.1%)
78 165 (46.6%)
99 189 (53.4%)
59 80 (23.3%)
115 263 (76.7%)
46 96 (27.1%)
40 80 (22.6%)
44 93 (26.2%)
48 85 (24.0%)
Neutrophils 
0.569
0.992
0.965
<0.0001
0.000
0.394
0.334
0.194
0.673
0.370
0.200
0.690
0.006
0.064
0.949
0.634
0.670
0.769
0.604
<0.0001
Supplementary Table S3: Univariate analysis of overall survival factors (ESPAC-Tplus 
cohort) 
 
  
Characteristic  Univariate analysis Multivariate analysis 
Age 0.99 (0.98 to 1.01) 
2=0.50 (P=0.48) 
 
Sex  Female  1(Referent)  
Male  0.93 (0.75 to 1.16) 
2=0.32 (P=0.36) 
 
Smoking  Never  1(Referent)  
Past  1.17 (0.91 to 1.51) 
2=3.87 (P=0.20) 
 
Present  1.35 (0.98 to 1.85) 
2=2.00 (P=0.05) 
 
Lymph Node 
Invasion  
Negative 1(Referent)  
Positive 2.00 (1.49 to 2.70) 
2=21.34 (P<0.0001) 
 
 
Resection 
Margin  
Negative 1(Referent)  
Positive 1.54 (1.24 to 1.92) 
2=15.16 (P<0.0001) 
 
Local 
Invasion  
No  1(Referent)  
Yes  1.29 (1.03 to 1.61) 
2=5.29 (P=0.02) 
 
Tumor 
Stage  
I 1(Referent)  
II 1.63 (0.92 to 2.89) 
2=14.68 (P=0.08) 
 
III 2.30 (1.33 to 3.95) 
2=3.00 (P=0.002) 
 
IV 1.52 (0.63 to 3.64) 
2=0.002 (P=0.34) 
 
 
Postoperative CA19.9 1.00 (1.00 to 1.01) 
2=22.39 (P<0.0001) 
 
 
Maximum tumor size 1.00 (0.99 to 1.00) 
2=2.70 (P=0.10) 
 
 
Differentiation 
status  
well 1(Referent)  
moderate 1.04 (0.69 to 1.56) 
2=2.65 (P=0.84) 
 
 
poor 1.27 (0.81 to 1.97) 
2=2.00 (P=0.28) 
 
WHO 
Performance 
score 
0 1(Referent)  
1 1.29 (1.01 to 1.65) 
2=4.44 (P=0.02) 
 
 
2 1.18 (0.81 to 1.72) 
2=2.00 (P=0.36) 
 
 CD3 Low 1(Referent) 1(Referent) 
High 0.70 (0.56 to 0.87) 
2=9.51 (P=0.002) 
0.71 (0.56 to 0.92) 
z-stat=-2.61 (P=0.008) 
 CD4 Low 1(Referent)  
High 0.79 (0.58 to 1.07) 
2=2.30 (P=0.12) 
 
 CD8 Low 1(Referent) 1(Referent) 
High 0.80 (0.64 to 1.01) 
2=3.27 (P=0.07) 
0.72 (0.54 to 0.96) 
z-stat=-2.24 (P=0.02) 
 CD68 Low 1(Referent) 1(Referent) 
High 0.78 (0.62 to 0.98) 
2=4.49 (P=0.03) 
0.85 (0.66 to 1.11) 
z-stat=-1.16 (P=0.24) 
 CD206 Low 1(Referent) 1(Referent) 
High 0.62 (0.47 to 0.82) 
2=11.31 (P=0.0007) 
0.55 (0.40 to 0.75) 
z-stat=-3.74 (P=0.0001) 
 Neutrophils Low 1(Referent) 1(Referent) 
High 1.08 (0.86 to 1.36) 
2=0.47 (P=0.49) 
1.01 (0.78 to 1.30) 
z-stat=0.08 (P=0.93) 
 Fibrolytic 1(Referent) 1(Referent) 
Stroma Inert 0.86 (0.63 to 1.18) 
2=3.58 (P=0.36) 
0.85 (0.60 to 1.20) 
z-stat=-0.91(P=0.36) 
 Dormant 0.79 (0.58 to 1.08) 
2=3.00 (P=0.14) 
0.97 (0.69 to 1.37) 
z-stat=-0.13 (P=0.89) 
 Fibrogenic 0.75 (0.55 to 1.03) 
2=0.31 (P=0.08) 
0.87 (0.62 to 1.23) 
z-stat=-0.75 (P=0.45) 
Concordance  0.60 ± 0.01 
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Supplementary Table S4: LIFETEST procedure between survival factors stratified according to stromal composition for immune infiltrates (ESPAC-Tplus cohort) 
 
  
  high_ 
dormant 
high_ 
fibrogenic 
high_ 
fibrolytic 
high_ 
inert 
low_ 
dormant 
low_ 
fibrognic 
low_ 
fibrolytic 
  PFS OS PFS OS PFS OS PFS OS PFS OS PFS OS PFS OS 
CD3 
high_fibrogenic 0.74 0.79             
high_fibrolytic 0.46 0.79 0.31 0.65           
high_inert 0.74 0.83 0.56 0.69 0.74 0.96         
low_dormant 0.25 0.65 0.11 0.48 0.74 0.79 0.53 0.79       
low_fibrogenic 0.36 0.48 0.21 0.35 0.78 0.65 0.56 0.65 0.88 0.79     
low_fibrolytic 0.04 0.35 0.01 0.21 0.15 0.48 0.11 0.48 0.31 0.65 0.34 0.88   
low_inert 0.21 0.51 0.10 0.35 0.59 0.65 0.34 0.65 0.88 0.83 0.74 0.89 0.34 0.79 
CD4 
high_fibrogenic 0.64 0.90             
high_fibrolytic 0.21 0.67 0.11 0.66           
high_inert 0.48 0.70 0.19 0.66 0.73 0.99         
low_dormant 0.24 0.71 0.12 0.66 0.83 0.90 0.64 0.90       
low_fibrogenic 0.19 0.51 0.11 0.51 0.64 0.66 0.43 0.70 0.73 0.90     
low_fibrolytic 0.48 0.66 0.33 0.66 0.83 0.90 0.73 0.90 0.89 0.90 0.73 0.90   
low_inert 0.98 0.96 0.83 0.90 0.64 0.90 0.73 0.90 0.60 0.90 0.26 0.51 0.43 0.90 
CD8 
high_fibrogenic 0.84 0.97             
high_fibrolytic 0.53 0.97 0.53 0.97           
high_inert 0.84 0.97 0.80 0.97 0.80 0.97         
low_dormant 0.53 0.97 0.53 0.97 0.84 0.97 0.61 0.97       
low_fibrogenic 0.93 0.97 0.84 0.97 0.80 0.97 0.84 0.97 0.53 0.97     
low_fibrolytic 0.50 0.97 0.50 0.97 0.77 0.97 0.53 0.97 0.84 0.97 0.53 0.97   
low_inert 0.53 0.97 0.53 0.97 0.93 0.97 0.80 0.97 0.82 0.97 0.77 0.97 0.77 0.97 
CD68 
high_fibrogenic 0.90 0.94             
high_fibrolytic 0.66 0.94 0.53 0.94           
high_inert 0.99 0.94 0.99 0.94 0.66 0.94         
low_dormant 0.66 0.94 0.51 0.94 0.99 0.94 0.60 0.94       
low_fibrogenic 0.99 0.94 0.99 0.94 0.75 0.94 0.99 0.94 0.70 0.94     
low_fibrolytic 0.41 0.94 0.41 0.94 0.66 0.94 0.41 0.94 0.82 0.94 0.51 0.94   
low_inert 0.51 0.94 0.41 0.94 0.82 0.94 0.53 0.94 0.99 0.94 0.53 0.94 0.90 0.94 
CD206 
high_fibrogenic 0.82 0.99             
high_fibrolytic 0.11 0.11 0.07 0.14           
high_inert 0.31 0.22 0.22 0.26 0.75 0.95         
low_dormant 0.01 0.00 0.00 0.00 0.25 0.01 0.09 0.01       
low_fibrogenic 0.33 0.11 0.25 0.11 0.92 0.50 0.83 0.50 0.26 0.14     
low_fibrolytic 0.36 0.39 0.28 0.39 0.96 0.99 0.83 0.92 0.39 0.11 0.92 0.79   
low_inert 0.78 0.50 0.52 0.50 0.75 0.92 0.92 0.99 0.25 0.06 0.86 0.67 0.87 0.92 
Neutrophils 
high_fibrogenic 0.90 0.75             
high_fibrolytic 0.37 0.75 0.37 0.75           
high_inert 0.37 0.75 0.51 0.79 0.87 0.90         
low_dormant 0.37 0.75 0.57 0.88 0.84 0.82 0.98 0.89       
low_fibrogenic 0.90 0.92 0.80 0.75 0.37 0.75 0.37 0.75 0.37 0.75     
low_fibrolytic 0.37 0.75 0.57 0.92 0.90 0.75 0.94 0.79 0.90 0.88 0.37 0.75   
low_inert 0.68 0.82 0.90 0.88 0.57 0.75 0.68 0.75 0.75 0.82 0.68 0.79 0.57 0.88 
Supplementary Table S5: LIFETEST procedure between survival factors stratified according resection margin (ESPAC-Tplus cohort) 
  Neg_high Neg_low Pos_high 
  PFS OS PFS OS PFS OS 
CD3 
Neg_low 0.00 0.01     
Pos_high 0.00 0.00 0.67 0.38   
Pos_low 0.00 0.00 0.15 0.17 0.26 0.38 
CD4 
Neg_low 0.14 0.29     
Pos_high 0.00 0.00 0.38 0.29   
Pos_low 0.00 0.01 0.08 0.19 0.23 0.29 
CD8 
Neg_low 0.08 0.26     
Pos_high 0.01 0.05 0.34 0.26   
Pos_low 0.01 0.05 0.16 0.14 0.26 0.29 
CD68 
Neg_low 0.00 0.00     
Pos_high 0.00 0.00 0.20 0.16   
Pos_low 0.00 0.00 0.46 0.86 0.39 0.16 
CD206 
Neg_low 0.36 0.34     
Pos_high 0.00 0.01 0.31 0.57   
Pos_low 0.00 0.00 0.04 0.01 0.05 0.00 
Neutrophils 
Neg_low 0.87 0.69     
Pos_high 0.02 0.05 0.01 0.01   
Pos_low 0.01 0.05 0.01 0.01 0.87 0.89 
 
  
Supplementary Table S6: LIFETEST procedure between survival factors stratified according resection margin for stromal composition (ESPAC-Tplus cohort) 
 
Neg_ 
dormant 
Neg_ 
fibrogenic 
Neg_ 
fibrolytic 
Neg_ 
inert 
Pos_ 
dormant 
Pos_ 
fibrogenic 
Pos_ 
fibrolytic 
 PFS OS PFS OS PFS OS PFS OS PFS OS PFS OS PFS OS 
Neg_fibrogenic 0.83 0.83             
Neg_fibrolytic 0.09 0.14 0.07 0.19           
Neg_inert 0.39 0.33 0.35 0.50 0.46 0.62         
Pos_dormant 0.02 0.05 0.01 0.07 0.52 0.38 0.09 0.14       
Pos_fibrogenic 0.09 0.07 0.07 0.14 0.93 0.62 0.44 0.33 0.49 0.62     
Pos_fibrolytic 0.01 0.07 0.01 0.14 0.44 0.59 0.09 0.31 0.85 0.63 0.49 0.89   
Pos_inert 0.01 0.05 0.01 0.07 0.46 0.31 0.07 0.14 0.71 0.83 0.19 0.38 0.71 0.59 
 
  
Supplementary table S7: LIFETEST procedure between survival factors stratified according to therapeutic arm (ESPAC-Tplus cohort) 
  5FU_high 5FU_low GEM_high 
  PFS OS PFS OS PFS  OS 
CD3 
5FU_low 0.30 0.35     
GEM_high 0.42 0.57 0.12 0.14   
GEM_low 0.01 0.14 0.12 0.55 0.00 0.05 
CD4 
5FU_low 0.02 0.25     
GEM_high 0.17 0.43 0.17 0.43   
GEM_low 0.87 0.91 0.19 0.43 0.78 0.78 
CD8 
5FU_low 0.00 0.10     
GEM_high 0.06 0.49 0.17 0.25   
GEM_low 0.02 0.16 0.17 0.39 0.90 0.39 
CD68 
5FU_low 0.29 0.38     
GEM_high 0.97 0.91 0.29 0.38   
GEM_low 0.29 0.41 0.88 0.43 0.29 0.41 
CD206 
5FU_low 0.02 0.00     
GEM_high 0.11 0.08 0.20 0.08   
GEM_low 0.14 0.31 0.20 0.66 0.19 0.51 
Neutrophils 
5FU_low 0.96 0.92     
GEM_high 0.91 0.97 0.91 0.92   
GEM_low 0.91 0.97 0.91 0.92 0.96 0.97 
 
 
  
Supplementary Table S8: LIFETEST procedure between survival factors stratified according to therapeutic arm for stromal composition (ESPAC-
Tplus cohort) 
  
 
5FU_ 
dormant 
5FU_ 
fibrogenic 
5FU 
_fibrolytic 
5FU_ 
inert 
GEM_ 
dormant 
GEM_ 
fibrogenic 
GEM_ 
fibrolytic 
 PFS OS PFS OS PFS OS PFS OS PFS OS PFS OS PFS OS 
5FU_fibrogenic 0.83 0.96             
5FU_fibrolytic 0.84 0.96 0.83 0.96           
5FU_inert 0.98 0.96 0.83 0.96 0.95 0.96         
GEM_dormant 0.83 0.96 0.95 0.96 0.83 0.96 0.84 0.96       
GEM_fibrogenic 0.83 0.96 0.95 0.96 0.83 0.96 0.83 0.96 0.95 0.96     
GEM_fibrolytic 0.83 0.96 0.83 0.96 0.83 0.96 0.83 0.96 0.83 0.96 0.83 0.96   
GEM_inert 0.95 0.96 0.83 0.96 0.95 0.96 0.95 0.96 0.83 0.96 0.83 0.96 0.83 0.96 
Supplementary Table S9: Multivariate analysis of immune stromal markers with independent prognostic variables (ESPAC-Tplus cohort). 
Covariate 
PFS OS 
HR (95% CI) z-stat P HR (95% CI) z-stat P 
Stroma  
 
Fibrolytic 1.00 (Referent) 1.00 (Referent) 
Inert 0.89 0.64-1.25 -0.63 0.52 1.01 0.71-1.44 0.09 0.92 
 Dormant 0.75 0.53-1.06 -1.90 0.10 0.88 0.62-1.27 -0.64 0.52 
 Fibrogenic 0.72 0.51-1.00 -1.92 0.05 0.86 0.61-1.21 -0.81 0.41 
CD3 expression  
 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.71 0.55-0.92 -2.51 0.01 0.74 0.56-0.96 -2.21 0.02 
CD4 expression  
 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.75 0.52-1.06 -1.59 0.11 0.84 0.58-1.22 -0.87 0.38 
CD8 expression  
 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.77 0.58-1.01 -1.84 0.05 0.74 0.56-0.99 -2.00 0.04 
CD68 expression  
 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.87 0.66-1.13 -1.00 0.31 0.89 0.68-1.18 -0.76 0.44 
CD206 expression  
 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.66 0.48-0.90 -2.61 0.008 0.58 0.42-0.79 -3.45 <0.001 
Lymph Node Invasion     
 Negative 1.00 (Referent) 1.00 (Referent) 
 Positive 2.18 1.38-3.46 3.35 <0.001 1.91 1.20-3.05 2.73 0.006 
Resection Margin     
 Negative 1.00 (Referent) 1.00 (Referent) 
 Positive 1.55 1.21-1.99 3.51 <0.001 1.54 1.20-1.98 3.38 <0.001 
Stage     
 I 1.00 (Referent) 1.00 (Referent) 
 II 0.95 0.50-1.80 -0.13 0.89 1.17 0.59-2.34 0.46 0.64 
 III 0.80 0.38-1.66 -0.59 0.55 1.14 0.53-2.43 0.33 0.73 
 IV 0.55 0.21-1.47 -1.17 0.29 0.87 0.31-2.42 -0.26 0.79 
Concordance 0.64 ± 0.01 0.63 ± 0.01 
AIC 2851.15 2704.17 
AIC of stroma-TILs biomarkers model 2792.91 2772.91 
Supplementary Table S10: Demographics, surgery and pathology features of the patients 
scored in validation cohort. 
Demographics Total 
Characteristics  N= 93 
Age Median (IQR) years 67(40-83) 
Sex  Female  42 (45.1%) 
  Male  51 (54.8%) 
ECOG N=66 
 0 39 (65.0%) 
 1 18 (30.0%) 
 2 3 (5.0%) 
Diabetic status N=91 
  No  53 (80.3%) 
  IDDM (Type 1) 5 (7.5%) 
  NIDDM (Type 2) 6 (9.0%) 
  Type 3 DM 2 (3.0%) 
Post-Op. CA 19-9 Median (IQR) U/l  
N=60 
96 (0-7950) 
Tumor grade N=87 
  Well 1 (1.0%) 
  Moderate 26 (28.5%) 
  Poor 64 (70.5%) 
Lymph Node invasion N=91 
 
Negative 30 (21.9%) 
Positive 61 (68.1%) 
Resection margin   N=91 
 
Negative 70 (76.9%) 
Positive 21 (23.1%) 
Local invasion N=87 
 No  52 (59.7%) 
 Yes  35 (40.3%) 
Tumor stage N=89 
  I 2 (2.1%) 
  II 8 (8.6%) 
  III 79 (85.8%) 
  IV 3 (3.2%) 
Perineural invasion N=87 
 No 24 (27.5%) 
 Yes  63 (72.5%) 
CD3 count  N=92 
 
Low 48 (52.1%) 
High 44 (47.9%) 
CD4 count N=92 
 Low 26 (28.2%) 
 High 66 (71.7%) 
CD8 count  N=92 
 
Low 53 (57.6%) 
High 39 (42.3%) 
CD68 count N=92 
 Low 37 (40.2%) 
 High 55 (59.8%) 
CD206 count  N=92 
 
Low 37 (40.2%) 
High 55 (54.7%) 
MPO count N=92 
 
Low 47 (51.0%) 
High 45 (49.8%) 
CD45+ cells 
Low 45 (48.3%) 
High 48 (51.7%) 
CD45+CD3+ cells 
Low 40 (53.7%) 
High 43 (46.2%) 
CD45+CD3+CD4+ cells 
Low 48 (51.6%) 
High 45 (48.3%) 
CD45+CD3+CD8+ cells 
Low 39 (41.9%) 
High 54 (58.1%) 
CD45+CD68+ cells 
Low 56 (60.2%) 
High 37 (39.8%) 
CD45+CD206+ cells 
Low 55 (40.8%) 
High 38 (59.2%) 
CD45+MPO+ cells 
Low 46 (49.4%) 
High 47 (50.6%) 
Stroma N=92 
 
Inert 20 (21.7%) 
Dormant 26 (28.2%) 
Fibrogenic 20 (21.7%) 
Fibrolytic 26 (28.2%) 
Supplementary Table S11: Univariate analysis of progression free survival and overall survival 
factors in validation cohort.  
Univariate analysis: Validation cohort (Immunohistochemistry) 
Characteristics PFS OS 
Sex 
Female  1(Referent) 1(Referent) 
Male  
0.93 (0.57 to 1.5) 
2=0.08 (P=0.77) 
1.09 (0.62 to 1.90) 
2=0.09 (P=0.76) 
Lymph node invasion 
Negative 1(Referent) 1(Referent) 
Positive 
1.46 (0.87 to 2.45) 
2=2.06 (P=0.15) 
1.07 (0.60 to 1.88) 
2=0.05 (P=0.82) 
Resection margin 
Negative 1(Referent) 1(Referent) 
Positive 
1.21 (0.67 to 2.20) 1.25 (0.60 to 2.60) 
2=0.42 (P=0.51) 2=0.36 (P=0.55)
Tumor grade 
Poor 1(Referent) 1(Referent) 
Moderate 
5.13 (0.29 to 0.90) 
2=2.0 (P=0.02) 
7.38 (0.41-1.32) 
2=2.0 (P=0.30) 
Well 
2.8 (NA) 
2=5.30 (P=0.99) 
3.00 (NA) 
2=1.03 (P=0.99) 
Local invasion 
No  1(Referent) 1(Referent) 
Yes  
1.21 (0.73 to 2.01) 
2=0.55 (P=0.45) 
1.46 (0.83 to 2.56) 
2=1.74 (P=0.18) 
Tumor stage 
I 1(Referent) 1(Referent) 
II 
0.09 (0.01 to 0.75) 
2=13.21 (P=0.02) 
0.02 (0.00 to 0.40) 
2=8.99 (P=0.01) 
III 
0.04 (0.00 to 0.26) 
2=3.00 (P<0.01) 
0.01 (0.00 to 0.25) 
2=3.00 (P<0.01) 
IV 
0.02 (0.00 to 0.59) 
2=0.01 (P<0.01) 
0.01 (0.00 to 0.29) 
2=0.02 (P<0.01) 
Perineural invasion 
Negative 1 (Referent) 1 (Referent) 
Positive 
2.06 (1.10 to 3.84) 2.14 (1.07 to 4.28) 
2=5.24 (P=0.02) 2=4.71 (P=0.03)
Post-operative CA19.9 
1.00 (1.00 to 1.00) 1.01 (NA) 
2=12.09 (P=0.005) 2= 0.14 (P=0.70)
CD3 count 
Low 1(Referent) 1(Referent) 
High 
0.5 (0.35 to 0.95) 
2=4.62 (P=0.03) 
0.54 (0.31 to 0.94) 
2=4.65 (P=0.03) 
CD4 count 
Low 1(Referent) 1(Referent) 
High 
0.82 (0.49 to 1.39) 
2=0.5 (P=0.48) 
0.72 (0.41 to 1.27) 
2=1.25 (P=0.26) 
CD8 count 
Low 1(Referent) 1(Referent) 
High 
0.58 (0.35 to 0.96) 
2=4.43 (P=0.03) 
0.81 (0.46 to 1.41) 
2=0.52 (P=0.47) 
CD68 count 
Low 1(Referent) 1(Referent) 
High 
0.80 (0.49 to 1.30) 
2=0.79 (P=0.37) 
1.26 (0.71 to 2.24) 
2=0.66 (P=0.41) 
CD206 count 
Low 1(Referent) 1(Referent) 
High 
1.86 (1.11 to 3.12) 
2=5.62 (P=0.01) 
1.68 (0.95 to 2.99) 
2=3.24 (P=0.07) 
MPO count 
Low 1(Referent) 1(Referent) 
High 
1.38 (0.84 to 2.26) 
2= 1.66 (P=0.19) 
1.46 (0.83 to 2.57) 
2=1.73 (P=0.18) 
Stroma  
Fibrolytic 1(Referent) 1(Referent) 
Inert 
0.69 (0.34 to 1.40) 
2=13.84 (P=0.31) 
0.55 (0.24 to 1.27) 
2=4.74 (P=0.16) 
Dormant 
1.04 (0.55 to 1.95) 
2=3.00 (P<0.88) 
1.02 (0.48 to 2.18) 
2=3.00 (P=0.94) 
Fibrogenic 
0.28 (0.13 to 0.59) 
2=0.003 (P<0.005) 
0.50 (0.25 to 1.06) 
2=0.19 (P=0.07) 
 
Supplementary Table S12: Multivariate analysis of individual immunohistochemistry markers in validation cohort 
Covariate 
PFS OS 
HR (95% CI ) z-stat P HR (95% CI) z-stat P 
CD3 count 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.22 0.10-0.46 -4.01 <0.001 0.26 0.11-0.58 -3.29 <0.001 
CD4 count 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.44 0.23-0.83 -2.51 0.01 0.62 0.33-1.16 -1.48 0.13 
CD8 count 
Low 1.00 (Referent) 1.00 (Referent) 
High 1.04 0.55-1.95 0.12 0.89 1.15 0.70-3.22 1.06 0.28 
CD68 count 
Low 1.00 (Referent) 1.00 (Referent) 
High 0.75 0.45-1.27 -1.03 0.29 1.10 0.60-2.03 0.33 0.74 
CD206 count 
Low 1.00 (Referent) 1.00 (Referent) 
High 4.08 2.08-8.00 4.09 <0.001 2.39 1.25-4.57 2.63 0.008 
Stroma 
Fibrolytic 1.00 (Referent) 1.00 (Referent) 
Inert 0.74 0.37-1.50 -0.06 0.94 0.67 0.28-1.06 -0.87 0.37 
Dormant 0.97 0.50-1.90 -0.82 0.40 1.13 0.50-2.57 0.31 0.75 
Fibrogenic 0.11 0.05-0.27 -4.87 <0.001 0.33 0.15-0.74 -2.67 0.007 
Concordance 0.76 ± 0.04 0.69 ± 0.04 
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Legends to supplementary figures:  1 
Supplementary figure S1: Schematic representation of image analysis using Image J 2 
algorithm. (A) Schematic representation for the algorithm used for intensity calculation. (B) 3 
Schematic diagram for the algorithm used for immunostained cell count. 4 
Supplementary figure S2: Inter-rater concordance in ESPAC cohort. (A) Plot depicting 5 
inter-rater reliability for H-Score for Picrosirius red/fast green staining with Inter-concordance 6 
coefficient (ICC), which is measure of concordance for continuous variables, as 0.84 (95%CI: 7 
0.82-0.85). (B) Plot showing inter-rater reliability for H-Score for a-SMA staining with ICC, as 8 
0.84 (95%CI: 0.82-0.85). ICC in the range of 0.75-1.00 is associated with excellent inter-rater 9 
concordance. (C-D) Plot depicting inter-rater reliability for Low/high stratification of for 10 
Picrosirius red/fast green staining with Cohen’s Kappa, which is a measure for inter-rater 11 
concordance for categorical variables, as 0.75 (95%CI: 0.72-0-77) and for a-SMA as 0.79 12 
(95%CI: 0.77-0.81). Cohen’s kappa in the range of 0.61-0.80 depict good concordance. 13 
Supplementary figure S3: Representative images of immunostaining illustrating low and 14 
high expression of -SMA, picrosirius red/fast red staining for Collagen, CD3, CD4, CD8, 15 
CD68, CD206 and chloracetate estarase staining for neutrophils. Values in inserts depict 16 
respective H-score/counts per mm3. 17 
Supplementary figure 4 Correlation matrix depicting correlations of intratumoral cells 18 
FACS analysis with immunohistochemistry staining and stratification. Correlation 19 
matrix involved inter-methodological comparisons for immune markers stained for CD3, CD4, 20 
CD8, CD68 and CD206. The methods involved were classical immunohistochemistry on 21 
histological blocks, immunocytochemistry on tissue-blocks prepared from isolated 22 
intratumoral cells, immunostaining on cytospins slides prepared from isolated intratumoral 23 
cells and FACS analysis of isolated intratumoral cells. FACS analysis for same immune 24 
markers of peripheral blood derived monocytes (PBMCs) served as reference. Solid square 25 
(black) in correlogram depict correlation between immunohistochemistry staining on 26 
tissueblocks with intratumoral cells FACS. Scatter plots in insert represent the correlation 27 
Legends to supplementary figures Click here to access/download;Supporting Document;13.
Mahajan et al 2018 Legends to supplementary figures v7.docx
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between individual immune markers. Each of the individual immune markers were stratified 1 
as low/high count. Dotted square (black) in correlogram depict correlation between 2 
immunohistochemistry staining on tissue-blocks with PBMCs FACS analysis. Number of 3 
stars in in correlograms are proportional to strength of agreement. P<0.05 considered 4 
statistical significant. 5 
Supplementary figure S5: Influence of SMA and collagen expression on progression 6 
free survival. (A) The Kaplan-Meier survival analysis shows that patients with low SMA 7 
expression did not show deviation in progression free survival time in comparison to high 8 
SMA expression. (B) The Kaplan-Meier survival analysis shows that patients with low 9 
collagen expression did not show deviation in progression free survival time in comparison to 10 
high collagen expression. (C) Tabular representation of LIFETEST procedure depicting 11 
combinations of stromal subtypes with respect to progression free survival. 12 
Supplementary figure S6: Contribution of multifaceted stromal composition in defining 13 
overall survival. (A) Kaplan-Meier survival analysis of patients with resected PDAC in 14 
respect to stroma subtype. (B) The Kaplan-Meier survival analysis shows that patients with 15 
low SMA expression did not show deviation in overall survival time in comparison to high 16 
SMA expression. (C) The Kaplan-Meier survival analysis shows that patients with low 17 
collagen expression did not show deviation in overall survival time in comparison to high 18 
collagen expression. (D) Tabular representation of LIFETEST procedure depicting 19 
combinations of stromal subtypes with respect to overall survival. 20 
Supplementary figure S7: Inferred leukocyte subtype frequencies associated with 21 
prognostic association in determining overall survival corresponding to stromal 22 
composition. (A) Random forest iterations illustrate variable of importance and minimal 23 
depth of the prognostic variables in determining progression free survival. Longer VIMP bars 24 
with shorter minimal depth bars indicate more important variables. Area shaded in grey 25 
depicts prognostic window for the prognostic variables. (B) Multivariate recursive partitioning 26 
for discrete-time survival tree for overall survival depicting prognostic signatures amalgating 27 
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two or more markers with median overall survival varying between 12.70 months to 29.20 1 
months. The variable selection in multivariate recursive partitioning for discrete-time survival 2 
tree for the overall survival model is based on random forest iterations and is an unbiased 3 
selection. Also, the multivariate recursive partitioning for discrete-time survival tree model is 4 
based on prognostic strength of individual biomarkers taken into consideration. As the 5 
prognostic strength is different for PFS and OS, prognostic signature of OS differ significantly 6 
than PFS. (C) Waterfall representation of each prognostic signature as delineated from the 7 
terminal nodes illustrating the relative prognostic index of each signature calculated using 8 
Cox multivariate proportional hazards. (D) Box plot depicts the distribution of prognostic 9 
indices with respect to individual prognostic signatures. P<0.05 considered significant. 10 
Supplementary figure S8: Prognostic associations of tumor stage, postOpCA19.9 and 11 
lymph node invasion and comparison of its composite signature with the histological 12 
signature. (A) By Random forest iterations we determined “variables of importance (VIMP)” 13 
and minimal depth of the prognostic variables in to predict progression free survival. Longer 14 
VIMP bars with shorter minimal depth bars indicate a higher effect/impact of the variable. 15 
Area shaded in grey depicts the prognostic window for the prognostic variables. (B) 16 
Multivariate recursive partitioning for discrete-time survival tree for progression free survival 17 
depicts the reference signature amalgating two or more markers with median progression 18 
free survival varying between 9.88 months to 19.71 months with a relative error of prediction 19 
given with 0.07 (X-error 0.01). (C) Survival ROC curve depicting comparison of histological 20 
signature with the reference signature. 21 
Supplementary figure S9: CONSORT diagram of independent validation cohort. 22 
Supplementary figure S10: Comparison of multiplex immunostaining with single 23 
immunohistochemistry staining in validation cohort. (A) Representative images of 24 
multiplex immunostaining with consecutive staining in order of haematoxylin (Nuclei), CD3, 25 
CD4, CD8,CD45, CD68,CD206, MPO, a-SMA and Collagen (Picrosirius red/ Fast green). 26 
Representative merged images of multiplex immunostaining for a PDAC TMA core. Images 27 
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in the insert depict enlarged images from white box. Tonsil multiplex immunostaining served 1 
as a control. (B) Scatter plots depicting correlation between classical immunohistochemistry 2 
and multiplex immunostaining followed by image cytometric analysis for markers, namely, 3 
CD3, CD4, CD8, CD68, CD206, MPO and a-SMA. (C) Tabular representation of the Kaplan-4 
Meier survival analysis depicting influence of high and low expression of immune infiltrate 5 
markers from immunohistochemistry staining, CD3, CD4, CD8, CD68, CD206 and 6 
neutrophils in predicting PFS and OS in validation cohort. (D) Kaplan-Meier curve 7 
representative actual response and predicted response predicted from prognostic histological 8 
signature derived from ESPAC-Tplus cohort. Dotted lines depict the curves for predicted 9 
response whereas solid lines represent curves for actual response. The accuracy of 10 
prediction in validation cohort using prognostic histological signature is 0.75 (95%CI: 0.64-11 
0.83, accuracy P>0.001). P<0.05 is considered as significant. 12 
Supplementary figure S11: Work flow-chart for multiplexing immunostaining and 13 
quantification image cytometric analysis. Work flow highlighted in grey area depict 14 
multiple antibodies staining cycle (multiplexing).  15 
Suppl Figure S1: Schematic representation of image analysis
Input Output
Label Area Mean StdDev Min Max IntDen %Area RawIntDen
1 10B.jpg (Colour[3]) 699300 0.92 15.3 0 255 644385 0.36 644385
2 10C.jpg (Colour[3]) 699300 0.26 8.13 0 255 181560 0.1 181560
3 10D.jpg (Colour[3]) 699300 0.45 10.74 0 255 316710 0.18 316710
4 10E.jpg (Colour[3]) 699300 0.22 7.44 0 255 151725 0.09 151725
5 10I.jpg (Colour[3]) 699300 4.64 34.09 0 255 3246405 1.82 3246405
6 10J.jpg (Colour[3]) 699300 2.81 26.64 0 255 1967325 1.1 1967325
7 10K.jpg (Colour[3]) 699300 1.27 17.96 0 255 888930 0.5 888930
8 10L.jpg (Colour[3]) 699300 0.68 13.16 0 255 476085 0.27 476085
9 10M.jpg (Colour[3]) 699300 3.15 28.15 0 255 2199630 1.23 2199630
10 10N.jpg (Colour[3]) 699300 1.2 17.44 0 255 837675 0.47 837675
11 10O.jpg (Colour[3]) 699300 1.93 22.12 0 255 1352010 0.76 1352010
12 11C.jpg (Colour[3]) 699300 1.35 18.48 0 255 941460 0.53 941460
13 11D.jpg (Colour[3]) 699300 0.49 11.14 0 255 340935 0.19 340935
14 11E.jpg (Colour[3]) 699300 6.45 40.05 0 255 4512480 2.53 4512480
15 11F.jpg (Colour[3]) 699300 4.11 32.13 0 255 2876910 1.61 2876910
16 11J.jpg (Colour[3]) 699300 1.68 20.63 0 255 1174530 0.66 1174530
17 11M.jpg (Colour[3]) 699300 1.29 18.09 0 255 902445 0.51 902445
18 11N.jpg (Colour[3]) 699300 1.72 20.9 0 255 1205640 0.68 1205640
19 11P.jpg (Colour[3]) 699300 0.15 6.26 0 255 107610 0.06 107610
20 12C.jpg (Colour[3]) 699300 3.08 27.88 0 255 2157045 1.21 2157045
21 12D.jpg (Colour[3]) 699300 1.29 18.08 0 255 901425 0.51 901425
22 12E.jpg (Colour[3]) 699300 4.28 32.77 0 255 2994720 1.68 2994720
23 12F.jpg (Colour[3]) 699300 2.07 22.89 0 255 1448910 0.81 1448910
24 12H.jpg (Colour[3]) 699300 4.41 33.25 0 255 3085500 1.73 3085500
(B)
(A)
Slice Count Total Area Average Size %Area
10b.jpg (Colour[3]) 11 760 69.09 0.12
10c.jpg (Colour[3]) 4 326 81.5 0.05
10d.jpg (Colour[3]) 3 193 64.33 0.03
10e.jpg (Colour[3]) 33 3417 103.55 0.56
10f.jpg (Colour[3]) 9 784 87.11 0.13
10i.jpg (Colour[3]) 30 2828 94.27 0.46
10j.jpg (Colour[3]) 32 3022 94.44 0.5
10k.jpg (Colour[3]) 16 1247 77.94 0.2
10l.jpg (Colour[3]) 32 2701 84.41 0.44
10m.jpg (Colour[3]) 30 2904 96.8 0.48
10n.jpg (Colour[3]) 29 2444 84.28 0.4
10o.jpg (Colour[3]) 64 6028 94.19 0.99
11b.jpg (Colour[3]) 26 2378 91.46 0.39
11c.jpg (Colour[3]) 10 934 93.4 0.15
11d.jpg (Colour[3]) 49 4179 85.29 0.68
11e.jpg (Colour[3]) 3 269 89.67 0.04
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Suppl Figure S2: Inter-rater concordance in ESPAC-Tplus cohort
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Suppl Figure S3: Representative IHC images with low/high categorization
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Suppl Figure S4: Correlation matrix depicting correlations of intra-tumoral cells comparing FACS with IHC staining
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Suppl Figure S5: Influence of a-SMA and collagen expression on progression
free survival.
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Suppl Figure S6: Contribution of stromal subcompartments to overall survival
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Suppl Figure S7: Prognostic histological signature for overall survival
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Suppl Figure S9: CONSORT diagram of validation cohort
Suppl Figure S10: Comparison of multiplex immunostaining with single
immunohistochemistry staining in validation cohort
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Suppl Figure S11: work-flow for the multiplex immunostaining and quantification
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